

**2009 NIDA  
International  
Forum June 19–23 • Reno, Nevada**

**Commonalities among the diseases of addiction:  
implications for treatment and prevention**

# Program Book



National Institute on Drug Abuse  
National Institutes of Health  
U.S. Department of Health and Human Services

---



**2009 NIDA  
International  
Forum June 19–23 • Reno, Nevada**

## Welcome to the 2009 NIDA International Forum

Welcome to the 14th NIDA International Forum. The meeting has become the International Program's primary research exchange activity because of the numerous opportunities it offers both NIDA and the international drug abuse research community to promote and sustain productive scientific partnerships across geographic borders and scientific disciplines. The NIDA International Program has always focused on making connections among scientists—helping individuals discover their commonalities—whether partnerships are built around similar areas of research, interpersonal and professional compatibility, geographic proximity, or shared experiences. Research presented by Forum participants has consistently demonstrated how individuals from diverse settings can successfully join forces to enhance local, national, and international public health efforts to address drug abuse and addiction.

Scientific research also has found that diseases of addiction have much more in common than was initially thought. Addressing this year's theme, *Commonalities Among the Diseases of Addiction: Implications for Treatment and Prevention*, presenters will discuss the physiological and subjective similarities among addictions to drugs of abuse, food, gambling, and sexual behaviors. Speakers also will explore promising insights into how outcomes improve when pharmacotherapies, behavioral interventions, and prevention programs address those commonalities.

One of the most satisfying parts of each NIDA International Forum is observing how participants take advantage of this scientific meeting to develop innovative research projects. The NIDA International Program appreciates the efforts by members of the International Society of Addiction Journal Editors, whose Web site, PARINT.org, and workshops during this and previous Forums promote peer-reviewed scientific articles reporting on international research projects.

This year, the NIDA International Program is pleased to support a second satellite to the Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). That meeting, *Treating Addiction During Pregnancy: Exploring Multinational Perspectives To Build a Treatment Approach Consensus*, gathers experts from around the world to advance research and treatment of pregnant women. Our thanks to the satellite chair, Dr. Hendrée Jones of Johns Hopkins University, and her co-chair, Dr. Gabriele Fischer of the Medical University of Vienna, for their leadership on this important topic. We appreciate the support of CPDD for both the NIDA International Forum and Treating Addiction During Pregnancy.

NIDA is pleased to have this opportunity to showcase your drug abuse research efforts. As you attend the plenary and breakout sessions and review the poster abstracts, you will notice both the quality of the research presented here and the important role the international research community plays in addressing the public health impacts of drug abuse and addiction.



Steven W. Gust, Ph.D.  
Director, International Program  
National Institute on Drug Abuse

## Contact Information

### **NIDA INTERNATIONAL PROGRAM STAFF**

---

NIDA International Program  
National Institute on Drug Abuse  
National Institutes of Health  
6001 Executive Boulevard  
Room 5274, MSC 9581  
Bethesda, Maryland 20892, USA

❖ **Steven W. Gust, Ph.D., Director**

Phone: +1-301-443-6480

Fax: +1-301-443-9127

E-mail: [ipdirector@nida.nih.gov](mailto:ipdirector@nida.nih.gov)

❖ **Dale S. Weiss, Program Analyst**

Phone: +1-301-402-6683

Fax: +1-301-443-9127

E-mail: [dweiss@nida.nih.gov](mailto:dweiss@nida.nih.gov)

### **IQ SOLUTIONS STAFF (SUPPORT CONTRACTOR)**

---

IQ Solutions, Inc.  
11300 Rockville Pike, Suite 901  
Rockville, Maryland 20852, USA

❖ **Kimberly Barnes, Project Director**

Phone: +1-301-984-1471, ext. 4299

Fax: +1-301-984-1473

E-mail: [kbarnes@iqsolutions.com](mailto:kbarnes@iqsolutions.com)

❖ **Nei-Hyun Park, Program Manager**

Phone: +1-301-984-1471, ext. 4069

Fax: +1-301-945-4296

E-mail: [npark@iqsolutions.com](mailto:npark@iqsolutions.com)

❖ **Lisa Jordre, Fellowship Administrator**

Phone: +1-301-984-1471, ext. 4276

Fax: +1-301-984-1473

E-mail: [ljordre@iqsolutions.com](mailto:ljordre@iqsolutions.com)

❖ **Judy McCormally, Technical Advisor**

Phone: +1-703-536-9209

Fax: +1-703-532-8116

E-mail: [judymccormally@gmail.com](mailto:judymccormally@gmail.com)

❖ **Deborah Casner, Senior Meeting Planner**


Phone: +1-301-984-1471, ext. 4245

Fax: +1-301-984-1473

E-mail: [dcasner@iqsolutions.com](mailto:dcasner@iqsolutions.com)

# Table of Contents

<b>Agenda .....</b>	<b>5</b>
<b>Speaker Presentation Summaries and Biosketches .....</b>	<b>13</b>
<b>Treating Addiction During Pregnancy .....</b>	<b>36</b>
<b>Hotel Map .....</b>	<b>48</b>





## Friday, June 19, 2009

---

2:30 p.m. – 8:30 p.m.

### Registration

*Outside East Elevators–2nd Floor*

3:00 p.m. – 5:30 p.m.

### International Society of Addiction Journal Editors (ISAJE) Workshops

Participants may choose to attend one workshop in person and the other workshop online before or after the Forum. Participants who agree to help evaluate the two training methods will receive a copy of the newly revised book, *Publishing Addiction Science* (2nd edition, Babor et al., 2008).

Breakout #1

### Practical Issues in Publishing Addiction Science

*Bonanza A*

Experienced journal editors will help published and unpublished researchers:

- ❖ Identify the most appropriate journal for their papers.
- ❖ Avoid common pitfalls between submission and acceptance.
- ❖ Understand how journals work.
- ❖ Gain confidence in writing and submitting articles.

**Chair:** Robert L. Balster, Editor, *Drug and Alcohol Dependence*

#### How To Choose a Journal

- ❖ Thomas F. Babor, Associate Editor, *Addiction*

#### Beyond the Anglo-American World: Advice to Researchers

- ❖ Isidore S. Obot, Editor, *African Journal of Drug and Alcohol Studies*

#### How To Write a Good Research Paper

- ❖ Peter Miller, Commissioning Editor, *Addiction*

#### How To Review Papers for a Scientific Journal

- ❖ Robert L. Balster, Editor, *Drug and Alcohol Dependence*

#### What Journal Editors Want Most From Prospective Authors: An Open Forum

Breakout #2

### Ethical Issues in Publishing Addiction Science

*Bonanza B*

Experienced journal editors, including a bioethicist, will address challenging ethical dilemmas faced by novice and experienced authors.

**Chair:** Thomas F. McGovern, Editor-in-Chief, *Alcoholism Treatment Quarterly*

#### Publication Issues for Graduate Students, Postdocs, and Junior Faculty

- ❖ Dominique Morisano, *Centre for Addiction and Mental Health/University of Toronto*

#### Authorship Credits

- ❖ Erin L. Winstanley, *University of Cincinnati College of Medicine*

*Friday, June 19, 2009 (continued)*

**The Seven Deadly Sins of Scientific Publishing**

- ❖ Thomas F. Babor, Associate Editor, *Addiction*

**Moral Reasoning in Addiction Publishing**

- ❖ Thomas F. McGovern, Editor-in-Chief, *Alcoholism Treatment Quarterly*

**Conflict of Interest in Relation to Funding Sources**

- ❖ Peter Miller, Commissioning Editor, *Addiction*

5:30 p.m. – 5:45 p.m.

**Break**

5:45 p.m. – 7:30 p.m.

**NIDA International Fellowship Programs Alumni Meeting *Bonanza B***

Meet Humphrey and INVEST Fellowship alumni to identify future collaborators for international addictions research or policy development.

- Co-Chairs:** Dale S. Weiss, *International Program, NIDA*  
J. Randy Koch, *Virginia Commonwealth University*

**Science for Global Health:**

**Funding Opportunities From the Fogarty International Center**

- ❖ James E. Herrington, *Fogarty International Center*

**Experiences in Developing Collaboration:**

**Union Alternative Georgia and University of Pennsylvania**

- ❖ David Otiashvili, *Union Alternative Georgia*
- ❖ George E. Woody, *University of Pennsylvania*

7:30 p.m. – 8:30 p.m.

**Welcome and Networking Session**

***Southern Pacific BCDE***

---

**Saturday, June 20, 2009**  
**NIDA International Forum: Symposium**

---

7:30 a.m. – 8:30 a.m.

**Registration**

***Outside East Elevators–2nd Floor***

8:30 a.m. – 11:45 a.m.

**Plenary Session**

***Rose B Ballroom***

8:30 a.m. – 9:00 a.m.

**Welcoming Remarks and Introduction**

**College on Problems of Drug Dependence (CPDD)**

- ❖ Flavio Pechansky, *Chair, CPDD International Committee*

**NIDA International Program**

- ❖ Steven W. Gust, *Director, International Program, NIDA*



9:00 a.m. – 10:30 a.m.

**Disorders of Desire: Shared Brain Vulnerabilities to Drug and Non-Drug Rewards**

Chair: Joseph Frascella, *Division of Clinical Neuroscience and Behavioral Research, NIDA*

**Common Brain Mechanisms in Addiction and Obesity**

❖ Joseph Frascella, *Division of Clinical Neuroscience and Behavioral Research, NIDA*

**Similar Brain Dysfunctions in Chemical and Non-Chemical Addictions**

❖ Wim van den Brink, *University of Amsterdam*

**Unbridled Passions: Overlapping Brain Substrates for Cue-Induced Drug and Sexual Desire**

❖ Anna Rose Childress, *University of Pennsylvania*

10:30 a.m. – 10:45 a.m.

**Break**

10:45 a.m. – 11:15 a.m.

**National Institute on Drug Abuse Progress, Priorities, and Plans for the Future**

❖ Timothy P. Condon, *Deputy Director, NIDA*

11:15 a.m. – 11:45 a.m.

**2009 NIDA International Program Awards of Excellence**

**Mentoring**

❖ James C. Anthony, *Michigan State University*

**International Leadership**

❖ Ian Stolerman, *King's College London*

**Collaborative Research**

❖ Steffanie Strathdee, *University of California, San Diego*

❖ María Remedios Lozada Romero, *Baja California, Mexico*

❖ Carlos Magis-Rodríguez, *CENSIDA, Mexico*

11:45 a.m. – 1:00 p.m.

**Optional Networking Lunch (Fee required)**

*Pavilion E*

12:30 p.m. – 4:15 p.m.

**Exhibits and Demonstrations of Collaboration, Training, and Research Tools and Opportunities**

*Rose B Ballroom*

Chair: Dale Weiss, *International Program, NIDA*

**NIDA International Virtual Collaboratory (NIVC)**

Explore the new Collaboration Matching Service and learn how to conduct live audio/video virtual meetings, create a discussion forum or wiki, add or retrieve information from the Resource Center, and register in the Profile Directory.

❖ Joseph G. Perpich, *JGPerpich, LLC*

❖ Krystyna Isaacs, *JGPerpich, LLC*

**International Drug, Alcohol and Tobacco (IDAT) Research Community**

Investigate this information hub designed to collect and disseminate the latest drug abuse research news from key organizations and researchers, and to provide online training tools, a comprehensive online data resource center, and collaboration tools such as workgroups.

❖ Rachel C. Gross, *Danya International, Inc.*

*Saturday, June 20, 2009 (continued)*

### **Drug Abuse Research Training Interactive Learning Modules**

Improve your skills in biostatistics, understanding the neurobiology of drug abuse, evaluating programs, and designing and managing clinical trials.

❖ John M. "Skip" Harris, Jr., *Medical Directions, Inc.*

### **Methadone Research Web Guide and Tutorial**

Assess your knowledge about methadone maintenance treatment and review this evidence-based educational tool prepared for an international audience of researchers, treatment providers, and policymakers.

❖ Kimberly Barnes, *IQ Solutions, Inc.*

### **International Programme in Addiction Studies**

Learn more about the online master of science degree jointly offered by the University of Adelaide (Australia), King's College London (United Kingdom), and Virginia Commonwealth University (United States).

❖ J. Randy Koch, *Virginia Commonwealth University*

### **International Drug Abuse Research Society (IDARS)**

Discover how you can contribute to this international scientific organization that fosters research and collaboration in molecular, cellular, and systems biology, including neuropharmacological, neurobehavioral, neurochemical, and neuroanatomical themes.

### **Hubert H. Humphrey Fellowship Program**

Talk with representatives of the U.S. Department of State and NIDA about these jointly supported fellowships for mid-career professionals from eligible countries.

❖ Edward Roslof, *Hubert H. Humphrey Fellowship Program*

**1:00 p.m. – 2:30 p.m.**

## **Concurrent Breakout Sessions**

**Breakout #1**

### **Ethical Issues in the Conduct of Research**

*Bonanza A*

Ethical issues cross cultures and boundaries. How can drug abuse researchers maintain confidentiality, resolve ethical dilemmas, minimize conflicts with DSM and ICD efforts, or co-exist with pharmaceutical companies?

**Chair:** Linda B. Cottler, *Washington University School of Medicine*

### **Ambiguity in Research Ethics With Hidden and Hiding Populations**

❖ Catherine L.W. Striley, *Washington University School of Medicine*

### **Ethical Issues Across Cultures**

❖ Linda B. Cottler, *Washington University*

**Breakout #2**

### **Multinational Assessment and Prevention of Inhalant Abuse**

*Bonanza B*

Researchers from around the world will report on efforts to identify household and industrial products that are abused by inhalation, their use patterns, and prevention interventions.

**Chair:** Debra Dell, *Canadian Youth Solvent Addiction Committee*

**Volatile Solvent Abuse Among Indigenous Youth: An Environmental Scan of Canada, Australia, Mexico, and the United States**

❖ Colleen Anne Dell, *University of Saskatchewan*

**Solvent Inhalant Abuse Among Street Children in Upper Egypt**

❖ Alaaeldin Elkoussi, *Assiut University College of Medicine*

**White Knight and Opal: Supply Reduction Approaches to Volatile Substance Misuse in Australia**

❖ Sarah MacLean, *Turning Point Alcohol and Drug Centre, Melbourne*

**Multinational Country Scan of Inhalant Abuse – Next Steps**

❖ M. Patricia Needle, *Consultant, NIDA*

2:30 p.m. – 2:45 p.m.

**Break**

2:45 p.m. – 4:15 p.m.

**Concurrent Breakout Sessions**

Breakout #1

**The New World of Naltrexone: New Formulations, New Indications** *Bonanza B*

Discuss new research findings on the safety and efficacy of oral and depot formulations of naltrexone for the treatment of opioid, methamphetamine, and alcohol use disorders.

**Co-Chairs:** Ivan Montoya, *Division of Pharmacotherapies and Medical Consequences of Drug Abuse, NIDA*

David R. Gastfriend, *Alkermes, Inc.*

**Blocking Opiate Effects at the Receptor for the Treatment of Addiction: An Historical Perspective of Naltrexone Research and Development**

❖ Richard L. Hawks

**New Formulations of Naltrexone in the United States**

❖ Sandra D. Comer, *Columbia University*

**Evaluation of New Formulations of Naltrexone for Opioid Dependence in Russia**

❖ Evgeny Krupitsky, *Pavlov Medical University*

**Naltrexone for Alcohol Dependence Around the World**

❖ David R. Gastfriend, *Alkermes, Inc.*

**Naltrexone for Methamphetamine Addiction in Scandinavia**

❖ Johan Franck, *Karolinska Institute*

**Discussant**

❖ Charles P. O'Brien, *University of Pennsylvania*

*Saturday, June 20, 2009 (continued)*

## Breakout #2

### The Interaction of Violence and Substance Use Affecting Women's Treatment and Interventions in the Global Arena: What Is Known and What Is Needed Next

*Bonanza A*

Violence and trauma contribute to substance abuse among women and impact prevention and treatment interventions. Presenters will report on their measures and findings, and discuss interventions that are being conducted to reduce trauma and could be translated globally to reach more vulnerable women.

**Chair:** Wendee M. Wechsberg, *RTI International*

#### **Women With Trauma and Substance Use Disorders: Research Findings and Options for Treatment Interventions**

❖ Denise A. Hien, *City University of New York and Columbia University*

#### **Issues of Global Violence Against Women Involved in Substance Abuse: An Australian Perspective**

❖ Lucy Burns, *Australian National Drug and Alcohol Research Centre*

#### **Reducing Violence Against Vulnerable Women: Data From a Randomized Clinical Trial in Pretoria, South Africa**

❖ Charles D. Parry, *Medical Research Council of South Africa*

## **Saturday, June 20, 2009**

### **Joint NIDA International Forum and CPDD Satellite**

---

8:00 p.m. – 10:00 p.m.

### **Treating Addiction During Pregnancy: Exploring Multinational Perspectives To Build a Treatment Approach Consensus** *Bonanza A*

This joint NIDA International Forum and CPDD Satellite Meeting will both initiate a global dialogue about the public health issue of drug addiction during pregnancy and determine the need and level of enthusiasm for a larger meeting to develop a consensus statement on the principles and best practices of drug addiction treatment for pregnant patients. The organizers thank Reckitt Benckiser Group Inc., which provided partial support for this meeting.

**Chair:** Hendree Jones, *Johns Hopkins University*

**Co-Chair:** Gabriele Fischer, *Medical University of Vienna*

#### **Introduction and Goals**

❖ Gabriele Fischer, *Medical University of Vienna*

❖ Hendree Jones, *Johns Hopkins University*

#### **The Ethics of Conducting Addiction Research With Pregnant Participants**

❖ Marianne Springer-Kremser, *Medical University of Vienna*

#### **The Treatment of Addiction During Pregnancy: State of Data in Australia**

❖ Lucy Burns, *Australian National Drug and Research Centre*

**The Real-Life Situation for Substance-Dependent Pregnant Women in France**

❖ Laurent Gourarier, *Maison Blanche Hospital, Paris*

**Evidence-Based Research on Methadone Maintenance During Pregnancy in Israel—  
Outcomes and Findings Related to Nicotine Dependence**

❖ Einat Peles, *Tel Aviv Sourasky Medical Center*

**Discussion and Next Steps**

❖ Gabriele Fischer, *Medical University of Vienna*

❖ Hendree Jones, *Johns Hopkins University*

---

**Monday, June 22, 2009**  
**Joint NIDA International Forum and CPDD Workshop**

---

8:00 p.m. – 10:00 p.m.

**International Research Posters**

***Rose Ballroom Foyer***

Learn about research conducted outside of the United States and meet NIDA staff and colleagues from around the world at this CPDD Workshop and NIDA International Forum Poster Session.

---

**Tuesday, June 23, 2009**  
**NIDA International Forum**

---

7:00 a.m. – 8:00 a.m.

**Forum Review/Future Planning**

***Southern Pacific EF***

Review this year's NIDA International Forum and help plan future meetings.

**Chair:** Steven W. Gust, *Director, International Program, NIDA*



### Thomas F. Babor, Ph.D., M.D., Associate Editor, *Addiction*

#### How To Choose a Journal

*Presentation Summary:* This presentation describes seven steps to find the most appropriate publication outlet for a scientific article or review paper. Information is provided on how to choose from approximately 85 addiction specialty journals, and guidance is given on the selection of more general disciplinary journals as well. The presentation describes the growth in publishing opportunities, types of journals, major steps in choosing a journal, and the reasons for choosing carefully. The process of choosing a journal includes deciding whether the article's audience is national or international in scope, considering whether to publish in a disciplinary or an addiction specialty journal, reviewing candidate journals in terms of their range and content, evaluating the journal's exposure, evaluating the probability of acceptance, and considering, but not being fooled by, the journal's "impact factor."

#### The Seven Deadly Sins of Scientific Publishing

*Presentation Summary:* This presentation is devoted to the ethical issues that are typically discussed in the context of scientific misconduct and research integrity. It reviews seven types of scientific misconduct in the context of a broader definition of scientific integrity. The seven "sins" are carelessness in citing and reviewing the literature; redundant publication; failure to declare a conflict of interest; unfair authorship; failure to conform to minimal standards of protection for animal or human subjects; plagiarism; and scientific fraud. Each of these ethical improprieties is discussed in terms of its relative importance, possible consequences, and procedures for avoiding them.

- ❖ **Dr. Thomas F. Babor** is a professor and chairman in the Department of Community Medicine and Health Care, University of Connecticut School of Medicine. He holds the university's Physicians Health Service endowed chair in Public Health and Community Medicine. Dr. Babor received his doctoral degree in social psychology from the University of Arizona and spent several years in postdoctoral research training in social psychiatry at Harvard Medical School. Subsequently, he served as head of social science research at McLean Hospital's Alcohol and Drug Abuse Research Center in Belmont, Massachusetts. In 1977, he received a Research Scientist Development Award from the National Institute on Alcohol Abuse and Alcoholism. During the course of this 5-year program, he studied alcoholism in France, investigated determinants of alcohol self-administration, and received training in public health concepts as applied to alcohol problems. In 1982, Dr. Babor moved to the Department of Psychiatry at the University of Connecticut School of Medicine, Farmington, Connecticut. He was the scientific director of the Alcohol Research Center between 1992 and 1994 and interim chair of the Department of Psychiatry between 1994 and 1998. He also has served as principal investigator of the Coordinating Center of Project MATCH, as well as several other multicenter clinical trials of treatment for alcoholism and drug abuse. Since 1997, he has been chairman of the Department of Community Medicine and Health Care at the University of Connecticut School of Medicine. He is associate editor-in-chief, as well as regional editor, of the international journal, *Addiction*. His research interests include screening, diagnosis, early intervention, and treatment evaluation, as well as alcohol and drug policy. He is the author or co-author of more than 130 articles published in peer-reviewed scientific journals and has written or edited more than 15 books and monographs. He is a co-author of *Alcohol: Ordinary Commodity Research and Public Policy*, which won first prize in the public health category of the 2004 British Medical Association's book competition.

### Robert L. Balster, Ph.D., Editor, *Drug and Alcohol Dependence*

#### How To Review Papers for a Scientific Journal

*Presentation Summary:* Most scientific journals use the peer review process to select articles for publication and to improve the quality of those articles which they accept for publication. Therefore, serving as a reviewer for articles submitted to journals is an important professional responsibility of scientists in the addiction field. This presentation will provide detailed information on the peer review process. It will provide information from the perspective of a journal editor on how reviewers are selected, what editors expect of reviewers, and how to be a good reviewer. The speaker will give insights into the peer review process, which can be of help in being a successful author as well as reviewer.

- ❖ **Dr. Robert L. Balster** is director of the Institute for Drug and Alcohol Studies, Luther A. Butler Professor of Pharmacology and Toxicology, and Research Professor of Psychology and Psychiatry at Virginia Commonwealth University (VCU), Medical College of Virginia campus in Richmond, Virginia. He is the editor-in-chief of the international journal *Drug and Alcohol Dependence* and president elect of the International Society of Addiction Journal Editors. Dr. Balster is the coordinator for the VCU site for the U.S. State Department/National Institute on Drug Abuse (NIDA) Humphrey Fellowship Program in Substance Abuse Prevention, Treatment, and Policy and a co-founder and co-director of the International Programme in Addiction Studies (<http://www.adelaide.edu.au/addiction/>), an online master's degree program. He is a fellow of the American College of Neuropsychopharmacology, the College on Problems of Drug Dependence (CPDD), and the American Psychological Association. He is a past president of CPDD and a former member of the World Health Organization Expert Advisory Panel on Drug Dependence (Dependence Liability Evaluation). Previous appointments also include chair of the Drug Abuse Clinical and Behavior Study Section at NIDA, chair of the U.S. Food and Drug Administration Drug Abuse Advisory Committee, and chair of the Board of Scientific Affairs of the American Psychological Association. In addition to publishing more than 270 papers in scientific journals, Dr. Balster has edited two books and authored 46 book chapters, including one on reviewing manuscripts for scientific journals for the 2nd edition of *Publishing Addiction Science* (<http://www.parint.org/isajewebsite/isajebook2.htm>). The principal areas of Dr. Balster's research include behavioral pharmacology, drug abuse potential assessment, inhalant abuse, and regulatory policy.

### **Kimberly Barnes, IQ Solutions, Inc.**

#### **Methadone Research Web Guide and Tutorial**

*Presentation Summary:* IQ Solutions, Inc., developed the *Methadone Research Web Guide and Tutorial* on behalf of the U.S. National Institute on Drug Abuse (NIDA) International Program. Designed to disseminate the results of NIDA-supported research on the discovery, testing, implementation, and efficacy of methadone maintenance treatment in the United States, the Web Guide also addresses emerging pharmacotherapies and regulatory approaches in several countries. The Web Guide educates the international community of drug abuse researchers, treatment providers, and policymakers by answering immediate questions and providing a roadmap for deeper investigation. A tutorial permits users to identify subject areas where they need more information, assess their understanding of the material, and print a personalized certificate of completion.

- ❖ **Ms. Kimberly Barnes** is the vice president of the Policy and Program Development team at IQ Solutions, where she has served as project director for the NIDA International Program for 10 years. For NIDA, Ms. Barnes managed efforts to adapt the 1995 publication, *Methadone Maintenance Treatment: Translating Research Into Policy*, into the interactive, Web-based training tool *Methadone Research Web Guide and Tutorial*, with research updates, links to resources addressing methadone treatment program implementation considerations, and a tutorial that allows users to test their knowledge and obtain a personalized certificate of completion. Ms. Barnes also helps the International Program manage initiatives such as the Small Business Innovation Research award to JGPerpich LLC to create the NIDA International Virtual Collaboratory, an online communications and collaboration tool, as well as the International Society of Addiction Journal Editors development of its Web site, Publishing Addiction Research Internationally ([www.PARINT.org](http://www.PARINT.org)). She has served as the International Program liaison with the international planning committee of the National Hispanic Science Network and the Inter-American Drug Abuse Control Commission at the Organization of American States, both key partners in the Institute's Latin American Initiative. Ms. Barnes has more than 15 years of experience in supporting the advancement of the National Institutes of Health's biomedical research agenda. Under her direction, the IQ Solutions team has provided research; analysis; program and policy planning, implementation, and evaluation; scientific peer review and clinical trial support; training and technical assistance; and logistical management services to 14 Offices and Institutes at the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration. Ms. Barnes holds a bachelor of science degree in industrial technology from the University of Maryland and is currently pursuing her master's degree.



### Lucy Burns, Ph.D., M.P.H., Australian National Drug and Alcohol Research Centre

#### Issues of Global Violence Against Women Involved in Substance Abuse: An Australian Perspective

*Presentation Summary:* The health outcomes for women with problematic substance use are poorer than those of their non-drug-using counterparts, particularly with respect to mental health and exposure to violence and trauma, and physical and/or sexual abuse by a partner, family member, or friend. Women with problematic substance use also have a higher prevalence of psychiatric comorbidity and have been noted to have attempted suicide and/or self-harm more often than women without problematic substance use. Overall, the interplay of drug use and a high-risk environment creates a situation in which women become highly vulnerable to a range of health conditions and traumas. The consequences of problematic substance use also are often more severe for women than men. This is largely due to physiological differences that result in women advancing more rapidly from substance use to dependence and hence developing related harms more quickly. Although women with problematic substance use have higher levels of mental and health disorders, are exposed to high levels of violence (both as children and adults), and often have more severe health issues arising from their substance use, the addiction literature has traditionally focused on men. Where women are the focus of research studies, it is often in the context of substance use in pregnancy and the impact of this use on parenting. This presentation is an overview of three recently undertaken Australian studies examining the extent of violence against women in three different samples: a clinical sample, a sample of homeless women, and hospital utilization patterns of women who are opioid dependent. Taken together, these three studies suggest a high level of violence in each of these cohorts and patterns of health care that demonstrate high rates of injury including head trauma. Overall, the profile of these women is one of severe disadvantage and poor health, despite residing in a wealthy and affluent society. The challenge for public health advocates therefore remains to identify opportunities to redress this major imbalance.

- ❖ **Dr. Lucy Burns** is a senior lecturer at the National Drug and Alcohol Research Centre in Sydney, Australia. She holds a master's of public health, Ph.D., and a graduate certificate in health policy. Her research interests include the epidemiology of alcohol and other drug use, with a focus on particularly vulnerable populations, such as people who are homeless and pregnant women. She is chief investigator for national drug monitoring systems (the Illicit Drug Reporting System and the Ecstasy and Related Drugs Reporting System) and manages a team of researchers examining the impact of flexible service provision on homeless people and the impact of alcohol and drugs on women.

### Anna Rose Childress, Ph.D., University of Pennsylvania

#### Unbridled Passions: Overlapping Brain Substrates for Cue-Induced Drug and Sexual Desire

*Presentation Summary:* Emerging brain, behavioral, and genetic data point to substantial overlap in the vulnerabilities for compulsive pursuit of drug and nondrug (e.g., food, sex, and money) rewards. Overlapping vulnerabilities have been linked both to the mesolimbic dopamine reward system and to its failed regulation by frontal regions. Dr. Childress will present evidence that the cues for cocaine and sexual reward activate similar brain substrates, and that the motivational states for both these rewards may begin instantly, outside conscious awareness—a modulation challenge.

- ❖ **Dr. Anna Rose Childress** has had a career-long interest in the painful paradox of addiction: relentless pursuit of a rewarding drug, despite profound negative consequences. Her research is characterizing the brain-behavioral vulnerabilities (e.g., powerful cue-triggered “GO!” states; ineffective “STOP!” circuits) that may help explain this paradox, with the goal of brain-targeted strategies to prevent relapse and to identify those at risk for addiction. She has an interest in the overlapping brain substrates for drug and nondrug (food, sex, gambling) reward; targeting these substrates may lead to “one-stop shopping” for the disorders of desire. Dr. Childress received her Ph.D. from Bryn Mawr College and completed a postdoctoral fellowship within the Department of Psychiatry at the University of Pennsylvania School of Medicine. She has conducted National Institutes of Health/National Institute on Drug Abuse (NIDA)-funded research within the Penn-VA Addiction Treatment Research Center since 1981 and is director of the Brain-Behavioral Vulnerabilities (Neuroimaging) Division at the center. Dr. Childress has regularly organized College on Problems of Drug Dependence (CPDD) symposia, workshops, and panels—often

integrating preclinical and clinical addiction science. She previously served on the CPDD Board of Directors (2004–2007) and Program Committee; she recently joined the Media Relations Committee and became CPDD president elect (2009). In addition to Dr. Childress' participation within CPDD, she is a member of the Society for Neuroscience and the American College of Neuropsychopharmacology. She has served as a regular and ad hoc member of NIDA study sections, as a member of the NIDA Board of Scientific Counselors, and as a frequent reviewer for scientific journals. Dr. Childress has been an active mentor for trainees in the addiction field (students, residents, NIDA T32 fellows, and NIDA K awardees), and she was director of the Advanced Psychology Fellowship Program and the Neuroimaging Core within the VA VISN 4 Mental Illness Research, Education and Clinical Center in Philadelphia.

IDAT—  
What's that?  
See page 46.

### **Sandra D. Comer, Ph.D., M.S., Columbia University**

- ❖ **Dr. Sandra D. Comer** is an associate professor of clinical neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons of Columbia University, and a research scientist at the New York State Psychiatric Institute. Dr. Comer received her undergraduate degree at Vanderbilt University (1987) and completed her graduate training at the University of Michigan, where she received her master of science (1988) and doctor of philosophy (1992) degrees for her research in the laboratory of Dr. James H. Woods on the effects of opioid drugs. Following graduate school, Dr. Comer completed a 2-year postdoctoral fellowship at the University of Minnesota, Minneapolis. There she received training in the laboratory of Dr. Marilyn Carroll on preclinical animal models of cocaine self-administration in rodents and nonhuman primates. In 1993, Dr. Comer began working at the Division on Substance Abuse at Columbia University, where she received training in human preclinical studies under the mentorship of Dr. Marian Fischman and Dr. Richard Foltin. Dr. Comer's research focus has been on the development and testing of novel approaches to the treatment of opioid dependence and the influences of sex, gonadal hormones, and drug use history on responses to pain and opioid medications. Dr. Comer served as a regular member of the National Institutes of Health Biobehavioral Regulation, Learning and Ethology (BRLE) study section, and is a voting member of the Institutional Review Board of the New York State Psychiatric Institute and of the Faculty Council of the Faculty of Medicine. Dr. Comer is the author or co-author of more than 70 papers, chapters, and books dealing with several aspects of substance abuse. She is a member of the College on Problems of Drug Dependence (CPDD), the American Psychological Association, and the International Study Group Investigating Drugs as Reinforcers. She received the prestigious Joseph Cochin Young Investigator Award from CPDD in 2004.

### **Timothy P. Condon, Ph.D., Deputy Director, National Institute on Drug Abuse**

- ❖ **Dr. Timothy P. Condon** was appointed deputy director of the National Institute on Drug Abuse (NIDA) in 2003. As deputy director, Dr. Condon supports the director in developing, implementing, and managing the Institute's programs, priorities, resources, policies, and research dissemination efforts. Dr. Condon has held a number of prominent science policy positions at NIDA since he arrived in 1992. He served as chief of the Science Policy Branch and acting deputy director of the Office of Science Policy and Communications (OSPC) until 1996 when he was appointed NIDA's first associate director for science policy and director of OSPC. In this capacity, Dr. Condon was responsible for the Institute's science planning, policy, congressional, and communications activities and coordinated NIDA's research training and science education programs. Before joining NIDA, Dr. Condon coordinated research and service programs at the former Alcohol, Drug Abuse, and Mental Health Administration for 4 years, serving as the deputy associate administrator for policy coordination and deputy associate administrator for science. From 1986 to 1989, he served as science policy analyst and project director at the U.S. Congress Office of Technology Assessment, where he directed an assessment of emerging technologies in the neurosciences. Dr. Condon received his Ph.D. in neuroscience from the Ohio State University College of Medicine. He pursued postdoctoral research in neuroendocrinology and neuropharmacology at the University of California at Los Angeles Brain Research Institute and at the Oregon Health Sciences University, where he joined the faculty in 1985.

### Linda B. Cottler, Ph.D., M.P.H., Washington University School of Medicine

#### Ethical Issues Across Cultures

*Presentation Summary:* Cross-cultural research presents intrinsic challenges that can compromise the quality and ethics of the conducted research. Preparation to conduct cross-cultural research should include cross-cultural ethics training. Examples from the National Institute on Drug Abuse and Fogarty International Center-funded research in India, Taiwan, and Australia will be highlighted to open a discussion of these cross-cultural issues.

- ❖ **Dr. Linda B. Cottler** is professor of epidemiology in the Department of Psychiatry at Washington University School of Medicine in St. Louis, Missouri, and director of the Epidemiology and Prevention Research Group. Her research has focused on addiction and its comorbidity with other disorders and consequences, such as HIV and sexually transmitted diseases (STDs). Specifically, her contributions include the development of widely used interviews for substance use and other psychiatric disorders, research on the consequences of substance use, nosological issues of addictions, and peer-delivered interventions to reduce high-risk behaviors that lead to HIV and other STDs. She was principal investigator for one of the largest National Institute on Drug Abuse (NIDA)-funded studies on MDMA use in Taiwan, Sydney, St. Louis, and Miami. She also is director of the new Clinical and Translational Science Award Center for Community-Based Research, which utilizes HealthStreet, a community-based site, to link underrepresented populations to research opportunities throughout Washington University. Because of her research involvement with hidden, vulnerable out-of-treatment respondents, such as drug users, female offenders, and re-entering offenders, she has actively worked to protect these populations while also working to enroll them in research studies. Dr. Cottler has mentored 30 postdoctoral or graduate students, is the director of a NIDA T-32 pre- and postdoctoral training program and a Fogarty International Center training program in India, and has won several awards for outstanding mentorship and service to the community. In the 25 years she has conducted research, she has published extensively, been on the editorial board of many journals, and consulted on numerous research studies, including World Health Organization multisite studies. As an ambassador with the McDonnell International Scholars Academy, she has ongoing collaborations with investigators at the Institute of Health Research at Chulalongkorn University and Songkla University in Thailand.

### Colleen Anne Dell, Ph.D., University of Saskatchewan

#### Volatile Solvent Abuse Among Indigenous Youth: An Environmental Scan of Canada, Australia, Mexico, and the United States

*Presentation Summary:* With support from the Social Sciences and Humanities Research Council of Canada International Opportunities Fund, researchers and community members from Australia, Mexico, Canada, and the United States have conducted country-specific environmental scans on the treatment of and healing from volatile solvent abuse (VSA) among indigenous youth. Our aim was to gather, analyze, and share information to develop an international research program. This session will share the results of the scans and the commonalities in circumstances that have contributed to VSA among indigenous youth (e.g., colonization, loss of culture) as well as unique responses from each country (e.g., prevention, treatment). Several areas have been identified as a focus for an international research program, including the role of resiliency and related culture-based coping skills in healing from VSA among indigenous youth; adaptation of residential VSA treatment in Canada to other indigenous populations; and the cross-cultural experience of the interrelated role of grief, trauma, and hallucinations as a risk factor for VSA and how best to address this.

- ❖ **Dr. Colleen Anne Dell** is an associate professor and research chair in substance abuse at the University of Saskatchewan in the Department of Sociology and School of Public Health. She also is a senior research associate with the Canadian Centre on Substance Abuse, Canada's national addictions agency. Her research is grounded in a community-based participatory approach. Her research interests include the relationship between identity and healing from drug addiction, substance abuse programming, self-harm among women and girls, the connection between youth resiliency and inhalant abuse, and equine-assisted learning as a healing approach to addictions. Her research areas are specific to aboriginal populations, criminalized women, and drug-using populations. Dr. Dell

is currently the lead on a collaborative national research project in partnership with the National Native Addictions Partnership Foundation and the Canadian Centre on Substance Abuse, which examines the impact of stigma in aboriginal women's treatment for problematic drug use. She also has worked extensively at the community and policy levels, including with the Elizabeth Fry Society of Manitoba and the Senate of Canada.

### **Debra Dell, Canadian Youth Solvent Addiction Committee**

- ❖ **Ms. Debra Dell** has been working in various capacities in the youth addictions field for 24 years. She has led and assisted in the development of many national and international solvent-specific addiction treatment centers, the most recent being White Buffalo Youth Inhalant Treatment Centre located on Sturgeon Lake First Nation, Saskatchewan, Canada, where she held the position of executive director for 7 years. Ms. Dell is currently the coordinator for the National Youth Solvent Addiction Committee and is working with 10 residential centers spread throughout Canada. She obtained her psychology degree from the University of Winnipeg, in addition to specialized counselling training through the University of Manitoba. Ms. Dell was involved in the development of a First Nations addictions-specific accreditation project through her involvement with Canada's Youth Solvent Abuse Network and the Canadian Council on Health Services Accreditation, and she participated in one of the first three centers in Canada to undergo and achieve national accreditation.

### **Alaaeldin Elkoussi, Ph.D., M.Sc., Assiut University College of Medicine**

#### **Solvent Inhalant Abuse Among Street Children in Upper Egypt**

*Presentation Summary:* The presentation summarizes a study of substance abuse among street children in southern Egypt that tracked the trends and patterns of abuse and identified the chemical and toxicological properties of the cheapest and most commonly abused substance, which is a glue called "Kolla." Data were collected from the street children using self-report surveys, interviews, informant reports, and focus group discussions. Physicochemical properties of Kolla were investigated using gas chromatography-mass spectrometry characterization and other methods.

**Need help  
publishing?  
See page 41.**

### **Johan Franck, M.D., Ph.D., Karolinska Institute**

#### **Naltrexone for Methamphetamine Addiction in Scandinavia**

*Presentation Summary:* There is no approved medication for the treatment of amphetamine dependence despite the widespread abuse of this type of psychostimulant drug. Animal studies have shown that naltrexone, a non-selective opioid receptor antagonist, reduces certain behavioral effects of amphetamine. We have recently shown that naltrexone reduces drug seeking in experimental models of amphetamine self-administration and modulates sensitized locomotor behavior. In human laboratory models, naltrexone blunts the subjective effects of amphetamine in both healthy subjects and amphetamine-dependent patients. The efficacy of naltrexone to increase weeks of abstinence in amphetamine-dependent patients was tested in a placebo-controlled trial. Eighty individuals meeting DSM-IV criteria for amphetamine dependence were randomized to either naltrexone or placebo treatment. All patients visited the clinic weekly to receive medication (50 mg naltrexone or identical placebo) and relapse prevention therapy. Urine samples were analyzed twice weekly for illicit drug use. The primary outcome measure was abstinence from amphetamine use, as measured by the total number of negative amphetamine urine samples during 12 weeks of treatment. Overall, 55 patients (68.7%) completed the study. The intention-to-treat analysis showed that the naltrexone group had a significantly higher number of amphetamine-negative urine samples compared to the placebo-treated group ( $p < 0.05$ ). There was a reduction in craving levels and self-reported weekly consumption of amphetamine over 12 weeks of treatment in the naltrexone group compared to the placebo group. Naltrexone had minimal side effects and was well tolerated. The results suggest that naltrexone is efficacious in reducing relapse to amphetamine use in amphetamine-dependent individuals.

- ❖ **Dr. Johan Franck** is head, Division of Psychiatry, Department of Clinical Neuroscience, Karolinska Institutet (KI), as well as director, Centre for Psychiatric Research and Education, KI, and adjunct professor of clinical addiction research, KI. He earned both his M.D. in 1987 and Ph.D. in 1992 at KI. In addition, he is a board-licensed physician and board-certified specialist in general psychiatry. He also earned a basic degree in psychotherapy in 1998. Dr. Franck serves on the board of directors, Department of Clinical Neuroscience; board of research and development, Stockholm County Health Care Provision; and board of research strategy, KI/Stockholm Health Care Provision. He also serves as the scientific counsel to the Swedish Prison and Probation Service.

### **Joseph Frascella, Ph.D., M.Sc., Division of Clinical Neuroscience and Behavioral Research, National Institute on Drug Abuse**

#### Common Brain Mechanisms in Addiction and Obesity

*Presentation Summary:* Emerging brain, behavioral, and genetic data point to substantial overlap in the vulnerabilities for compulsive pursuit of drug and nondrug (e.g., food, sex, and money) rewards. Overlapping vulnerabilities have been linked both to the mesolimbic dopamine reward system and to its failed regulation by frontal regions. Dr. Frascella will present evidence that low dopamine (DA) D2 receptor availability, a feature linked to increased cocaine administration in primates, occurs not only in several drug addictions but also in obesity.

- ❖ **Dr. Joseph Frascella** is currently the director of the Division of Clinical Neuroscience and Behavioral Research at the National Institute on Drug Abuse (NIDA), where he heads a broad drug abuse and addiction program of translational research and research training in clinical neuroscience, human development, and behavioral treatment. Dr. Frascella also has served for several years as the chief of the Clinical Neurobiology Branch as well as the program director of NIDA's basic pain research and basic research training programs. Before coming to NIDA, Dr. Frascella directed a neurophysiology research program at the Armed Forces Radiobiology Research Institute in Bethesda, Maryland; prior to that, he held the position of assistant professor within the Department of Psychology at Brown University. Dr. Frascella received an A.B. in biopsychology from Hamilton College, and an M.Sc. and a Ph.D. degree in experimental psychology/neuroscience from Brown University.

### **David R. Gastfriend, M.D., Alkermes, Inc.**

#### Naltrexone for Alcohol Dependence Around the World

*Presentation Summary:* Naltrexone is a mu-opioid receptor antagonist. The Food and Drug Administration approved the oral formulation for the treatment of opioid dependence and the depot formulation for the treatment of alcohol dependence. New formulations and new indications of naltrexone have been investigated in different parts of the world, and the results are encouraging. This presentation will review new research findings about the safety and efficacy of new formulations of naltrexone for the treatment of alcohol use disorders and discuss the use of naltrexone for alcohol dependence in different parts of the world.

- ❖ **Dr. David R. Gastfriend** is vice president for scientific communications at Alkermes, Inc., where he is involved in research, education, and scientific publication on behalf of the company's efforts in the field of addiction treatment. For over two decades, he served on the faculty of Harvard Medical School, most recently as associate professor of psychiatry and director of the addiction research program at Massachusetts General Hospital (MGH). While there, he founded the Fellowship in Addiction Psychiatry at MGH and provided clinical care to substance abuse patients. One of the few physicians in the country to be certified both in addiction medicine by the American Society of Addiction Medicine (ASAM) and in addiction psychiatry by the American Board of Neurology and Psychiatry, Dr. Gastfriend has conducted studies of both pharmacologic and behavioral treatments of alcohol and drug use disorders. He initiated the first multisite study to validate and refine the Patient Placement Criteria published by ASAM, for which he was funded for 7 years by the National Institute on Drug Abuse (NIDA). In 2001, he was the

recipient of a 5-year Mid-Career Investigator Award for Patient-Oriented Research from NIDA. In 2007, he received a "Champion in Health Care-Innovator Award" from the *Boston Business Journal* for work on behalf of Vivitrol®. Dr. Gastfriend also was a co-principal investigator on NIDA's Cocaine Collaborative Psychotherapy Study and the National Institute on Alcohol Abuse and Alcoholism's collaborative study COMBINE. He served two terms on the board of directors of ASAM, chairing its Treatment Outcome Research Committee and also served on the board of directors of the International Society of Addiction Medicine. An author or editor of more than 125 scientific publications, his editorial board membership has included the *Journal of Substance Abuse Treatment*, *Journal of Addictive Diseases*, and *Journal of Computers in Human Services*, for which he is associate editor. He is co-editor of the leading book on treatment matching in the field, *The ASAM Patient Placement Criteria for Substance-Related Disorders*, and editor of *Addiction Treatment Matching*. Dr. Gastfriend received his B.S. at Haverford College in Philadelphia, Pennsylvania, and his M.D. from Jefferson Medical College in Philadelphia, Pennsylvania.

### **Rachel C. Gross, Ph.D., CHES, Danya International, Inc.**

#### **The International Drug, Alcohol and Tobacco (IDAT) Research Community**

*Presentation Summary:* The International Drug, Alcohol and Tobacco Research Community ([www.idatresearch.com](http://www.idatresearch.com)) is dedicated to advancing drug, alcohol, and tobacco abuse research around the world by harmonizing the work of key global research partners and institutions, effectively managing and disseminating information, and providing research capacity and technological tools to advance the exchange of ideas and generate collaborative research. The site is a hub that collects and disseminates the latest research news from key leading organizations and researchers, provides online training, has multiple funding and resource databases, and supports networking tools to facilitate collaborative work. The site also has a toolkit that contains such things as international drug, alcohol, and tobacco abuse survey data and measures, clinical trials information, and statistical training. For most of the site's features, it is not necessary to sign in; however, to begin accessing the site's networking features, such as looking up member profiles and setting up online workgroups, the user can log into Exchange. Here, investigators can network and form workgroups. An online, peer-reviewed journal is available on this site, where original research can be submitted for publication.

- ❖ **Dr. Rachel C. Gross** is currently a senior project director at Danya International, Inc., a company that provides innovative services and solutions in such areas as public health communications, research and evaluation, information technology, and health product development, a perfect venue for Dr. Gross' interest in the utilization of technology in health communications. Dr. Gross has extensive training and experience in psychosocial research as well as health communications. In addition to conducting research on such topics as HIV/AIDS, drug abuse, and tobacco use, she also has conducted research to inform and evaluate a number of health communication programs. Prior to coming to Danya International, she worked at the Academy for Educational Development in Washington, DC, where she collaborated on multiple international health communication research projects pertaining to HIV/AIDS and avian influenza. Dr. Gross received her undergraduate degree in psychology from Smith College and her doctorate degree in public health from the Johns Hopkins Bloomberg School of Public Health. After graduate school, Dr. Gross did postdoctoral training as an Oak Ridge Institute for Science and Education Fellow at the United States Army Center for Health Promotion and Preventive Medicine. In addition to her current position at Danya International, Dr. Gross holds an adjunct professor position at Trinity University in Washington, DC.

### **Steven W. Gust, Ph.D., National Institute on Drug Abuse International Program**

- ❖ **Dr. Steven W. Gust** has directed the National Institute on Drug Abuse (NIDA) International Program since 1999. He is responsible for the Institute's efforts to foster rigorous collaborative and peer-reviewed international research and promote cooperation between NIDA and other U.S. agencies, foreign governments, and international, regional, and nongovernmental organizations. Dr. Gust oversees NIDA's efforts to build research capacity, administering fellowships for postdoctoral scientists and mid-career drug abuse professionals from low- and middle-income countries as well as research exchange programs for senior scientists. To disseminate NIDA's research methods,

findings, and tools to international scientists and organizations, Dr. Gust supervises NIDA's international scientific exchange activities, the NIDA International Program bimonthly E-News Letter, and the NIDA International Program Web page. Before assuming leadership of the NIDA International Program, Dr. Gust served as deputy and acting director of the Institute's Office on AIDS and as a special assistant to the director responsible for research on the medical uses of marijuana. He joined NIDA in 1986 as acting chief of the Clinical and Behavioral Pharmacology Branch, Division of Clinical Research, and has served as chief of the Research Section for the NIDA Division of Applied Research Workplace Performance Research Branch. Dr. Gust also conducted research at the University of Minnesota and the Minnesota Department of Health. In 1993, Dr. Gust received a prestigious appointment as a congressional fellow, where he worked with the U.S. Senate Labor and Human Resources Committee and the late Senator Paul Wellstone (D-Minnesota). He has served on the Surgeon General's Advisory Group on the Health Effects of Smokeless Tobacco; the Transportation Research Board Committee on Alcohol, Other Drugs, and Transportation; and the White House Health Care Reform Task Force.

### **John M. Harris, Jr., M.D., M.B.A., Medical Directions, Inc.**

- ❖ **Dr. John M. (Skip) Harris, Jr.**, is the president of Medical Directions, Inc. (MDI), a position he has held since 1995. MDI develops and markets educational programs for health professionals via The Virtual Lecture Hall ([www.vlh.com](http://www.vlh.com)). The company also does extensive research in online medical education, having received 10 National Institutes of Health research grants and published 11 peer-reviewed articles in this field. Prior to founding MDI, Dr. Harris served as a medical director and senior executive in national managed care organizations, including CIGNA Healthcare (Northern California, Seattle, and Tucson) and Wellpoint Health Networks (Woodland Hills, California). He has worked as a managed care consultant to organizations such as Medalia Health Care and Pharmacia Corporation. Dr. Harris is a board-certified internist. Before entering full-time medical education and management, he practiced internal medicine with the Palo Alto Medical Foundation and the U.S. Army. During the Iranian revolution, 1977–1979, he was assigned to Tehran as a U.S. Army Major and served as the Army's internal medicine consultant to the Middle East. Dr. Harris has authored numerous peer-reviewed publications on medical education, managed care, disease management, and the use of diagnostic tests.

### **Richard L. Hawks, Ph.D.**

#### **Blocking Opiate Effects at the Receptor for the Treatment of Addiction: An Historical Perspective of Naltrexone Research and Development**

*Presentation Summary:* This discussion will briefly review the history of the development of opiate antagonists as treatments for opiate addiction and the development in particular of naltrexone and its sustained release forms. Naltrexone was first synthesized in 1967 and approved for use as a treatment for opiate addiction in 1984. It has had limited impact on addiction treatment due to a limited acceptance by substance abusers seeking treatment. While the specific reasons for this lack of acceptance are not completely understood, it is clear that antagonist treatment in general, whether for narcotics or alcoholism, has not met with general clinical success. The primary issue associated with this failure is thought to be a breakdown in compliance with naltrexone's daily dosage regimen. Naltrexone antagonist treatment has only proven successful in situations where strong motivational factors have served to maintain this compliance. The daily dosing regimen was recognized as a potential problem in the 1970s when efforts were initiated at the National Institute on Drug Abuse to develop a sustained release form of naltrexone, on the assumption that less frequent dosing would improve compliance. For a variety of reasons, a clinically useful form of such a product has been a long time in coming, arriving on the market only in recent years. Evidence is now accumulating that seems to support the original assumption that motivational factors coupled with less frequent dosing requirements can lead to more positive outcomes for antagonist treatment of relapse of opiate addiction.

**2009 Award  
of Excellence  
recipients.  
See page 44.**

- ❖ **Dr. Richard L. Hawks** served as the deputy director for the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (formerly the Division of Treatment Research and Development [DTRD]) at the National Institute on Drug Abuse (NIDA) from 1999 to 2008. He was chief of the Chemistry and Pharmaceutics Branch of the Division and chief of the Research Technology Branch in the Division of Preclinical Research at NIDA during the 10 years prior to the formation of DTRD in 1990. In 1972, he began his career with the Federal Government as a chemist with the Division of Narcotic Addiction and Drug Abuse, National Institute of Mental Health—the Division that evolved into NIDA—following his Ph.D. in organic chemistry from Duke University in 1970 and a postdoctoral appointment at the Research Triangle Institute in North Carolina where he worked on cannabinoid chemistry. Dr. Hawks played a pivotal role in the U.S. Department of Health and Human Services' response to marijuana herbicide eradication health issues that surfaced in the late 1970s and chaired the committee that developed the U.S. Government's guidelines for accreditation of laboratories engaged in urine drug testing in the 1980s. In conjunction with this, he was a member of the United Nations Narcotic Commission Expert Consultative Group on the Detection and Assay of Controlled Drugs in Body Fluids (1989–1992). During this time, he also was responsible for the NIDA Drug Supply Program that supported the research of hundreds of research investigators in the United States and abroad. He was closely involved with the establishment of NIDA's medications development program in the early 1990s and the establishment of the new Division responsible for that program. Throughout these three decades, he developed programs, monitored projects, and generally assisted NIDA's grantees and contractors in a variety of areas of research and development associated with chemistry, pharmaceutics, and the development process of new medications for addiction treatment. He has participated as a consultant for many parts of the Federal Government, including the U.S. Congress, the U.N. Laboratories in Vienna, pharmaceutical companies, and other institutions in areas that include urine drug testing, designer drugs of abuse, and medication development.

### **James E. Herrington, Ph.D., M.P.H., Fogarty International Center**

#### **Science for Global Health: Funding Opportunities From the Fogarty International Center**

*Presentation Summary:* This presentation will provide an overview of the global burden of disease, with case examples, a prospective look at future trends in global morbidity and mortality, and a brief description of the National Institutes of Health (NIH) structure and function, with emphasis on the intra- and extramural training programs at NIH. Specific to global health, the presentation will describe the NIH Fogarty International Center and its funding of research and research training programs and opportunities. Case examples will be presented of how the Center invests in the training of both U.S. and foreign pre- and postdoctoral students in global health research. Finally, the presentation will wrap up with the 10 Best Buys in Global Health and ask the question of how can international research institutions, like NIH, improve our ability to promote brain circulation in the basic biomedical and behavioral sciences in order to be successful in achieving these 10 Best Buys in Global Health.

- ❖ Dr. James E. Herrington has more than 25 years of experience in international public health. In 2005, Dr. Herrington was appointed director, Division of International Relations, Fogarty International Center, the National Institutes of Health (NIH), where he leads the development of new and strategic partnerships between U.S. scientists and researchers abroad to advance translational research and training in the biomedical and behavioral sciences. Prior to NIH, he worked for the Centers for Disease Control and Prevention, the International Planned Parenthood Federation, and the University of North Carolina School of Medicine. Dr. Herrington's career has focused primarily on Africa and the Caribbean, with long-term assignments in Côte d'Ivoire, Haiti, Nigeria, and Senegal. Dr. Herrington holds a Ph.D. in environmental health and epidemiology from Colorado State University, an M.P.H. from the University of North Carolina at Chapel Hill, and a B.S. from Texas A&M University. His research interests include behavioral epidemiology, risk perceptions, vector-borne and immunizable infectious diseases, and the communication of science and technology. The author of articles in peer-reviewed journals, Dr. Herrington also serves as an anonymous reviewer for the *American Journal of Prevention Medicine*, *American Journal of Public Health*, and *Health Behavior and Education*. His secondary languages include French and Wolof. Dr. Herrington is from Oklahoma and is a member of the Chickasaw tribe.



### Denise A. Hien, Ph.D., M.S., City University of New York and Columbia University

#### Women With Trauma and Substance Use Disorders: Research Findings and Options for Treatment Interventions

*Presentation Summary:* Twenty years of epidemiology confirms the strong co-occurrence of traumatic stress-related disorders, such as post-traumatic stress disorder, and addictive disorders among women in community treatment in the United States. Despite wide recognition of the comorbidity between trauma and substance use, however, few interventions have been adopted systematically into women's treatment for addictions. The National Institute on Drug Abuse's (NIDA's) Clinical Trials Network (CTN) provided an ideal venue to examine the impact of cognitive behavioral therapy for women with trauma in community drug treatment settings. This presentation will highlight the "Women and Trauma" study conducted in NIDA's CTN, presenting relevant background and alternative treatment models. The presenter was lead investigator of this study, the largest randomized clinical trial of trauma-focused behavioral therapy in a real-world setting. Overall, this multisite study yielded many encouraging findings for the field, supports the positive impact of implementing group therapies for this special population, and offers an equal number of provocative questions for future research. The presentation will expose participants to this unique multisite clinical trial, using the exploration of trial findings to illuminate tensions between questions of efficacy and effectiveness in psychotherapy research. Implications for global applications of evidence-based approaches for psychotherapeutic treatment of trauma and substance comorbidity also will be emphasized. Finally, secondary analysis from the study will highlight additional risk behaviors and suggest ways in which cognitive behavioral therapies may be used to inform future work addressing sexual risk in this population.

- ❖ **Dr. Denise A. Hien** is a professor of clinical psychology at City University of New York and maintains a joint appointment as a senior research scientist in the Department of Psychiatry at Columbia University College of Physicians and Surgeons. She also is the founding executive director of the Women's Health Project in the Department of Psychiatry at St. Luke's/Roosevelt Hospital Center, a specialty treatment program for women with trauma and addictions which serves as a training center for pre- and postdoctoral psychology, social work, and psychiatry fellows. Over the past 17 years, with continuous funding from the National Institute on Drug Abuse, Office of Research on Women's Health, and National Institute on Alcoholism and Alcohol Abuse (18 grants total, including 6 R01 and 1 multisite), she and her team have conducted research that has helped to characterize the psychosocial and diagnostic correlates of interpersonal violence among inner-city minority women and their families. She also has contributed to science on the treatment of trauma-related disorders with substance comorbidity, conducting single and multisite clinical trials across the United States in community-based substance abuse treatment settings. Dr. Hien has authored and co-authored extensively in scientific journals, and presented at national and international conferences. She is considered a leader in the field of women's trauma and addiction treatment and has recently published a new book (January 2009) with her collaborators on the subject with the American Psychological Association Press, offering practical support to community providers and programs who want to integrate trauma services for women in substance abuse treatment.

Join NIDA's  
virtual  
collaboratory.  
See page 40.

### J. Randy Koch, Ph.D., Virginia Commonwealth University

- ❖ **Dr. J. Randy Koch** is currently the executive director of the Institute for Drug and Alcohol Studies at Virginia Commonwealth University (VCU) in Richmond, Virginia, and he also is the associate coordinator for the VCU Humphrey Fellowship Program in Substance Abuse Prevention, Treatment, and Policy. Dr. Koch earned his doctorate in community psychology at Michigan State University in 1985. Prior to joining VCU in 2003, he was the director of research and evaluation for the Virginia Department of Mental Health, Mental Retardation, and Substance Abuse Services, a position he held since 1989. Dr. Koch has conducted research in university, state government, and private for-profit organizations. His research interests include co-occurring substance use and mental health disorders, adolescent substance abuse, the etiology and prevention of youth tobacco use, program performance and outcome measurement, and the dissemination of science-based interventions.

## **Evgeny Krupitsky, M.D., Ph.D., Pavlov Medical University**

### **Evaluation of New Formulations of Naltrexone for Opioid Dependence in Russia**

#### *Presentation Summary:*

**Background:** The major problem with oral naltrexone formulation is insufficient compliance. Long-acting sustained release formulations of naltrexone (injectable or implantable) might improve compliance and, in turn, increase efficacy of heroin dependence treatment.

**Methods:** A total of 190 recently detoxified heroin addicts were randomized to a 6-month course of biweekly drug counseling and one of three medication groups: naltrexone implant (1,000 mg, 3 times – every other month) + oral placebo daily (NI+OP) (66 subjects); placebo implant + oral naltrexone (PI+ON) (50 mg/day) (62 subjects); and double placebo (implant and oral) (PI+OP) (62 subjects). Medications were administered under double-dummy/double-blind conditions. Urine drug testing and brief psychiatric evaluations were done at each biweekly visit. Oral medication compliance was evaluated using a urine riboflavin marker.

**Results:** Treatment Effectiveness Score (TES—a sum of heroin-positive and missed urines) revealed a clear advantage of the naltrexone implant group over the two other groups ( $p < 0.01$ ). At the end of 6 months, TES in the NI+OP group was 63 percent compared to 87 percent in the PI+ON group and 86 percent in the PI+OP group. Survival analysis also revealed a significantly greater retention in the NI+OP group compared to the two other groups ( $p < 0.01$ ). The number of non-surgical adverse events was limited with no difference between groups; however, surgical side effects (wound infections, local site reactions) were higher in the NI+OP group (6% of all implantations) compared to the two other groups (1%).

**Conclusion:** The long-acting sustained release naltrexone implant was safe and more effective than oral naltrexone and placebo for relapse prevention to heroin dependence.

- ❖ **Dr. Evgeny Krupitsky** is chief of the Department of Addictions at St. Petersburg Bekhterev Research Psychoneurological Institute and chief of the Laboratory of Clinical Psychopharmacology of Addictions at St. Petersburg State Pavlov Medical University, Russia. Since 2006, he also has held the position of adjunct professor of psychiatry in the Department of Psychiatry, University of Pennsylvania. He received his medical degree from the Leningrad Institute of Hygiene and Sanitation in 1983, and a Ph.D. in psychopharmacology from the Leningrad Institute of Experimental Medicine in 1988. In 1998, he also received a doctor of medical sciences in addiction psychiatry degree from St. Petersburg Bekhterev Research Psychoneurological Institute. Dr. Krupitsky worked as a visiting exchange scientist in the Department of Psychiatry at Yale University in 1996–1997. He has received several national and international awards including the European College of Neuropsychopharmacology Fellowship Award (1997), Heffter Research Institute Award for Outstanding Research in Hallucinogens (2000), and Award of the Government of the Russian Federation for Outstanding Research in Medicine (2005). Dr. Krupitsky is a member of the Research Society of Alcoholism, College on Problems of Drug Dependence, International Society for Biomedical Research in Alcoholism, Russian Association of Addiction Psychiatrists, and others. He has published many papers in Russian and international psychiatric journals, and he also is an author of several chapters in international manuals and two books on the treatment of alcoholism and addictions published in Russian. Dr. Krupitsky has been a co-principal investigator on several National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism grants. His major research interests include the following: clinical trial of a new pharmacotherapy for alcoholism and addictions; human psychopharmacology of alcoholism and addictions (opiate antagonists, NMDA receptor ligands); comorbidity of drug addictions, alcoholism, and HIV; and behavioral interventions to reduce HIV risk behavior in drug addicts and alcoholics.

## **Sarah MacLean, Ph.D., Turning Point Alcohol and Drug Centre, Melbourne**

### **White Knight and Opal: Supply Reduction Approaches to Volatile Substance Misuse in Australia**

*Presentation Summary:* Supply reduction measures have been part of many apparently successful anti-volatile substance misuse (VSM) strategies in Australia. Nonetheless, the effects of these interventions on VSM prevalence and harm have

only rarely been evaluated. This paper outlines the limited available evidence on two broad approaches to VSM supply reduction and how they have been implemented in Australia: product modification and measures restricting sales of affected products. One example of product modification has been the use of low-hydrocarbon vehicle fuel, known as Opal, in more than 70 Australian aboriginal communities. An evaluation of the impact of introducing Opal, conducted in 20 selected communities, found that petrol sniffing had declined in 17 of the 20, and that overall sniffing prevalence had declined by 70 percent compared with pre-Opal levels. Australian jurisdictions prohibit the sale of specified VSM products where the vendor could reasonably be expected to know the goods are intended for misuse; however, prosecutions under this legislation are very rare. Some also have introduced statutory restrictions on the sale of specified VSM products to persons under 18 years, yet the effect of such legislation remains unclear. Local evaluations indicate that targeting retailers to implement voluntary restrictions on VSM product sales has been an effective strategy when introduced through a local community development process.

- ❖ **Dr. Sarah MacLean** is a postdoctoral research fellow at Turning Point Alcohol and Drug Centre in Melbourne, Australia. She is a sociologist with a sustained interest in analyzing and contributing to the development of health and welfare policies and interventions, particularly as they affect marginalized and young people and users of alcohol and other drugs. She has a particular research interest in inhalant use. In 2007, Dr. MacLean completed her Ph.D. research, a qualitative and interpretive study of the meanings of inhalant use and the implications of various understandings of the practice for policies and interventions addressing inhalant use. She has published in national and international peer review journals including *International Journal of Drug Policy*; *Drugs*; *Contemporary Drug Problems*; *Drug and Alcohol Review*; *Journal of Youth Studies*; and *Youth Studies Australia*. Recently, she co-authored *Volatile Substance Misuse: A Review of Interventions* (2008) with associate professor Peter d'Abbs. The review has been published by the Australian Commonwealth Department of Health and Ageing as part of the National Drug Strategy Monograph series ([http://www.health.gov.au/internet/main/publishing.nsf/Content/73AFC6ADE4DEED9CCA25746B00834DA8/\\$File/vol-sub-mis-rvw-int.pdf](http://www.health.gov.au/internet/main/publishing.nsf/Content/73AFC6ADE4DEED9CCA25746B00834DA8/$File/vol-sub-mis-rvw-int.pdf)).

### **Thomas F. McGovern, Ed.D., M.A., LPC, LMFT, Editor-in-Chief, *Alcoholism Treatment Quarterly***

#### Moral Reasoning in Addiction Publishing

**Presentation Summary:** The road to unethical publication pitfalls described in the presentation by Thomas F. Babor is paved with good intentions. This presentation discusses many of the same issues in the context of a framework for ethical decision-making. The framework shows how to evaluate a given ethical dilemma in terms of the following key principles that can be used in moral reasoning and decision-making: autonomy, beneficence, nonmaleficence, justice, fairness, and stewardship. Case studies are used to illustrate the seven ethical topics, with a commentary on each case provided to demonstrate a practical approach to making sound decisions.

- ❖ **Dr. Thomas F. McGovern** is a professor in the Department of Psychiatry, Texas Tech University Health Sciences Center, Lubbock, Texas. He is program director of the Healthcare Ethics/Humanities Program for the School of Medicine. In addition, he serves as the chair of the Clinical Healthcare Ethics Committee for the Texas Tech University Medical Center and also for the School of Medicine. He has served as a clinician, educator, and researcher in a variety of educational and pastoral settings. He received his M.A. in history from Texas Tech University in 1968 and his Ed.D. in educational psychology–counseling from the same institution in 1983. His doctoral work dealt with the relationship between grief and depression in the treatment of alcoholism. He has identified a grieving process as a distinctive feature of alcoholism. He has been active in all aspects of the addiction field in his clinical, educational, and research activities. His role in the development of a code of ethics for the addiction field has been significant; in this capacity, he chaired the Ethics Committee for the National Association of Alcoholism and Drug Abuse Counselors. As a pioneering force in the development of institutional health care committees, Dr. McGovern has been instrumental in developing codes of ethics for hospitals, ambulatory clinics, and other health care institutions. His work in ethics, grief, and addiction has been published in journals, and he has made presentations at regional, national, and international conferences. He edits the *Alcoholism Treatment Quarterly* and serves on the editorial boards of other journals. As a member of an Institute

of Medicine committee, he was one of the authors of *Broadening the Base of Treatment for Alcohol Problems* (1990). His contributions to the addiction field were recognized in his honor as a National Counselor of the Year by the National Association of Alcoholism and Drug Abuse Counselors 1986. In 1998, he was honored by the College of Education, Texas Tech University as a Distinguished Alumnus. He has served on many boards at local, state, and national levels, which address the needs of patients and families experiencing long-term illnesses.

### **Peter Miller, Ph.D., Commissioning Editor, *Addiction***

#### **Conflict of Interest in Relation to Funding Sources**

*Presentation Summary:* This presentation describes recent trends in industry sponsorship of scientific research and the ethical risks involved in accepting funding from industry sources. Ethical issues related to academic relationships with the alcoholic beverage industry, tobacco industry, gambling industry, and pharmaceutical companies are considered. There are ultimately few simple right or wrong choices about which funding to accept or reject. However, it is vital that researchers go through an ethical assessment to consider the issues involved. This presentation explores the ways in which different interest groups have influenced the research process before demonstrating the use of the PERIL analysis—a type of ethical decision-making framework developed specifically for this issue.

- ❖ **Dr. Peter Miller** is the commissioning editor of the journal *Addiction*. He also is a National Health and Medical Research Council Howard Florey Fellow at the School of Psychology, Deakin University in Australia. Prior to this, he was a senior clinical research fellow at the National Addictions Centre, Institute of Psychiatry, King's College London and the Maudsley Hospital. That position focused on the evaluation of the Randomized Injectable Opiate Treatment Trial in South London—a national prescription heroin trial. He also acted as “Addictions Advisor” to The Pilgrim Trust and the J. Paul Getty Jr. Charitable Trust, which involved the assessment of drug-related funding applications and the management of grants worth approximately £3 million per year. Prior to this, he was a research fellow at Turning Point Alcohol and Drug Centre (Australia), a position he held for 7 years. Dr. Miller has conducted research into needle and syringe programs, overdose prevention, and treatment effectiveness for more than 10 years and also has been a lecturer in sociology at Deakin University. He is an active member of the International Society of Addiction Journal Editors and is an author in the book *Publishing Addiction Science*. He has edited one book and has more than 40 peer-reviewed articles as well as numerous government reports. His research interests include alcohol and other drug use in rural and regional populations and centers, alcohol-related violence in licensed venues, prescription heroin trials, suicide-related behavior in alcohol and other drug users, drug trend monitoring, Internet research, and treatment outcome evaluation. He also has a strong interest in harm reduction theory and ethics, particularly the behavior of funding bodies in influencing the research process. His current fellowship commenced in December 2007 to develop a quality-of-life (subjective well-being) measure for alcohol and drug users.

### **Ivan D. Montoya, M.D., M.P.H., Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse**

- ❖ **Dr. Ivan D. Montoya** received his M.D. from the University of Antioquia (Colombia) and a master's in public health from the Johns Hopkins School of Public Health, and completed residency training in psychiatry at the San Vicente de Paul Hospital (Colombia) and the University of Maryland Hospital (Baltimore). He was a Hubert H. Humphrey Fellow in Drug Abuse at the Johns Hopkins School of Public Health and a visiting postdoctoral fellow at the Intramural Research Program of the National Institute on Drug Abuse (NIDA). He has been the director of the Public Mental Health Program at the University of Antioquia (Colombia), director of the Practice Research Network of the American Psychiatric Association, consultant for the World Health Organization's Pan American Health Organization, and clinical director of the Pharmacotherapies and Medical Consequences Grants of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA) of NIDA. He currently is the acting deputy director of DPMCDA. He has published extensively in the areas of etiology, prevention, treatment (pharmacological and nonpharmacological), and medical consequences of drug abuse.

### Dominique Morisano, Ph.D., Centre for Addiction and Mental Health/University of Toronto

#### Publication Issues for Graduate Students, Postdocs, and Junior Faculty

*Presentation Summary:* In recent years, there has been increasing pressure on graduate students, postdoctoral fellows, master's degree students, and even research assistants and lab technicians to write or co-author scientific publications. This presentation describes the challenges and rewards of publishing early in one's professional career, including authorship issues, timetables, ethical dilemmas, and pressures to publish. The general issues related to authorship are first discussed and followed by the more specific topic of publishing graduate-level theses. The latter focuses on the entire process of thesis publication, ranging from issues that might come up prior to writing one's thesis all the way to eventual post-publication submission to an appropriate journal. In addition, special attention is given to the challenges encountered by students or novice investigators in less resourced countries.

- ❖ **Dr. Dominique Morisano** is a first-year postdoctoral fellow in addiction and mental health research and psychologist (supervised practice) at the Centre for Addiction and Mental Health (CAMH), University of Toronto School of Medicine. She is currently fulfilling requirements for her license in clinical psychology with the College of Psychologists of Ontario. She completed her Ph.D. in school/applied child psychology at McGill University in 2008, and her Sc.B. at Brown University in 2001. Dr. Morisano has many interests in the area of addiction science. Her current research interests lie in two main areas: (1) personal goal setting and (2) youth substance use, abuse, and addiction (causes, prevention, treatment, and outcomes). She is currently leading two studies at the University of Toronto and in the CAMH Biobehavioural Addictions and Concurrent Disorders Laboratory, the first focusing on the specific effects of chronic cannabis dependence on neurocognitive functioning in males with schizophrenia, and the second focusing on the effects of an indirect and brief online goal-setting tool on problem drinking behavior in university students.

Get a master's degree in addiction studies online. See page 47.

### M. Patricia Needle, Ph.D., Consultant, National Institute on Drug Abuse

#### Multinational Assessment of Inhalant Abuse Next Steps

*Presentation Summary:* Dr. M. Patricia Needle will present a brief summary and update on the activities of the Inhalant Working Group (IWG). Following the preparation and recent publication of an article on "Classification of Abused Inhalants" in the journal *Addiction*, the IWG set two tasks as next steps for the development of an international research agenda on inhalants/volatile solvents for the National Institute on Drug Abuse. These responsibilities are: Task I, titled "Develop multi-country survey of key country informants on use of inhalants/volatile substances," and Task II, titled "Develop inhalant user international survey questions." During this session, we will update participants on the work of the IWG in the past year—both progress and challenges—and propose some recommendations for advancing this agenda.

- ❖ **Dr. M. Patricia Needle** is currently consultant to the National Institute on Drug Abuse (NIDA) International and AIDS Research Programs, National Institutes of Health. She also served as director of the NIDA International Program for a number of years before being seconded to direct the executive secretariat for the 2002 International AIDS Conference in Barcelona. During her tenure with NIDA, Dr. Needle was responsible for establishing the NIDA international fellowship programs, organized the International Forum at the College on Problems of Drug Dependence, and has participated in all but one of these meetings. She has planned and implemented more than 30 international meetings and has successfully linked researchers from many countries to establish international research collaborations in the area of HIV/AIDS and drug abuse. Dr. Needle's current research and program focus areas include inhalants, HIV/AIDS and drug abuse, fellowship training, and the development of collaborative regional networks in Eurasia and Latin America.

## Isidore S. Obot, Ph.D., M.P.H., Editor, *African Journal of Drug and Alcohol Studies*

### Beyond the Anglo-American World: Advice to Researchers

*Presentation Summary:* This presentation deals with the challenges encountered by addiction scientists whose first language is not English and/or who work in countries with few resources. The presentation covers the practical and professional issues faced by these scientists, how authors from these countries can improve their chances of publishing in English-language journals, the possibility for authors to publish in both English and an additional language so they can communicate to a different audience, and how to decide whether an article serves the public best by being published in the author's mother tongue or in a local or regional journal.

- ❖ **Dr. Isidore S. Obot** is a professor of psychology, University of Uyo, and director, African Centre for Research and Information on Substance Abuse, Uyo, Nigeria. Before his appointment in Uyo in 2008, he served as tenured professor and chair, Department of Behavioral Health Sciences, Morgan State University School of Public Health. He also held the post of a scientist in the Department of Mental Health and Substance Abuse at the World Health Organization, Geneva, and taught psychology for 17 years at the University of Jos, Nigeria, where he started his academic career in 1985. Dr. Obot received a doctoral degree in social psychology from Howard University in Washington, DC, in 1983 and a master of public health degree from the Harvard University School of Public Health, Boston, in 1984. He has published widely in the areas of alcohol and drug abuse epidemiology, prevention, and policy in Africa. In 2000, he became the founding editor-in-chief of the *African Journal of Drug and Alcohol Studies*, a journal he continues to edit today. He also serves on the editorial boards of several addiction and psychology journals, including *Addiction*; *Drug and Alcohol Dependence*; *Behavioral Medicine*; *Substance Abuse Treatment, Prevention, and Policy*; and the *Journal of Psychology in Africa*. Dr. Obot has consulted for several organizations on substance abuse issues, including the World Health Organization, the United Nations Office on Drugs and Crime, the Economic Community of West African States, and the Nigerian National Drug Law Enforcement Agency. He is a member of many professional bodies in psychology and public health and remains active in research, editing, and teaching.

## Charles P. O'Brien, M.D., Ph.D., University of Pennsylvania

- ❖ **Dr. Charles P. O'Brien** earned M.D. and Ph.D. degrees from Tulane University. He received residency training at Harvard University, Tulane University, University of London, and University of Pennsylvania in internal medicine, neurology, and psychiatry and became board certified in both neurology and psychiatry. As chief of psychiatry at the Philadelphia VA Medical Center, he was responsible for more than 9,000 psychiatric patients. Despite this large clinical responsibility, he was able to establish and direct a clinical research program that has had a major impact on the treatment of addictive disorders. His research group has been responsible for numerous discoveries described in more than 500 publications that have elucidated basic information on the nature of addiction and improved the results of treatment for addictive disorders. His work includes the discovery of central nervous system changes involved in relapse, new medications, behavioral treatments, and instruments for measuring the severity of addictive disorders. He led the discovery of the effects of alcohol on the endogenous opioid system and demonstrated a completely new treatment for alcoholism. Many of his discoveries are now utilized in common practice for the treatment of addictive disorders throughout the world. Dr. O'Brien's recent work has focused on a genetic subtype of alcoholism. A functional allele of the  $\mu$  opiate receptor predicts response to alcohol and carries an increased risk of both alcoholism and opiate addiction. Dr. O'Brien's group reported a significant improvement in outcome among alcoholics when carriers of this allele were randomized to treatment with the opiate receptor antagonist naltrexone. This finding was replicated recently by another group. His group also recently discovered a medication that has shown efficacy against cocaine addiction, and there is already a preliminary report of a replication. His work is on the cutting edge of new treatments for addictive disorders. Dr. O'Brien was elected to the Institute of Medicine (IOM) of the National Academy of Sciences in 1991. He has received numerous research awards as well as an honorary doctorate from the University of Bordeaux in 1994 and the Nathan B. Eddy award for research on addiction from the College on Problems of Drug Dependence in 2003. He has been an adviser on drug policy to local and national governments since the 1970s, has chaired or served

as a member of numerous IOM committees dealing with the science and policy issues of abused drugs, and is currently chair of the substance use disorders committee for DSM-V. He is past president of the American College of Neuropsychopharmacology and the Association for Research in Nervous and Mental Disease. Currently, he is Kenneth Appel Professor and vice chair of psychiatry at the University of Pennsylvania, vice director of the Institute of Neurological Sciences, and director of the Center for Studies of Addiction.

### David Otiashvili, M.D., Union Alternative Georgia and George E. Woody, M.D., University of Pennsylvania

#### Experiences in Developing Collaboration: Union Alternative Georgia and University of Pennsylvania

*Presentation Summary:* This presentation will describe the process of a developing collaboration between research teams from the Republic of Georgia and the University of Pennsylvania and highlight its milestones. The collaboration started with a professional affiliation completed by Dr. Otiashvili during his year as a Humphrey Fellow in 2003–2004 when he spent time with Dr. Woody and other members of the Pennsylvania/Veterans Administration (Penn/VA) Center for Studies of Addiction. The National Institute on Drug Abuse (NIDA) International Program's support in identifying the research team for the affiliation was crucial, and an interest in opioid addiction treatment as a way to prevent the spread of HIV was identified. Discussions continued online and during and after meetings, such as the College on Problems of Drug Dependence and a NIDA meeting held in Kiev in April 2008. These discussions focused on the nonmedical, injecting use of buprenorphine (Subutex) in Georgia and the fact that little or no research had been done to study ways to treat it. As a result, we began working on a R21 NIDA proposal to obtain pilot data on the short-term impact of daily Suboxone vs. daily methadone treatment for reducing or stopping Subutex injecting. As part of these efforts, Dr. Woody applied for a NIDA INVEST/CTN Research Fellowship in which Dr. Gvantsa Piralishvili, an addiction psychiatrist working with methadone patients in Tbilisi, would spend a year at the Penn/VA Center. The application was approved, and Dr. Piralishvili arrived in early April 2007 and returned to Tbilisi at the end of March 2008. During this fellowship year, she spent time observing the conduct of several treatment outcome studies, including the NIDA START study, a clinical trial investigating whether there is any evidence that Suboxone maintenance is associated with liver damage. Dr. Piralishvili studied the protocol for this and other projects, visited the methadone clinic where the study was being done, attended staff meetings where clinical research issues were discussed, and took online courses in human subjects protections and other aspects of clinical research that are recommended or required by the National Institutes of Health. She, Dr. Woody, and Dr. Otiashvili prepared and submitted the R21 proposal that they had discussed at meetings and online, requesting 2 years of funding to compare daily Suboxone treatment with daily methadone treatment for Subutex injectors. It received a good priority score but was not funded, so it will be revised and resubmitted. Major outcomes of this developing collaboration have been put in place including the elements of a strong partnership, an increased capacity of the Georgian research team to understand and conduct NIDA research, and a greater understanding by U.S. researchers of the local social and cultural environment in which drug use is occurring in the Republic of Georgia.

- ❖ **Dr. David Otiashvili**, a psychiatrist, has studied addiction research at the Johns Hopkins University as a National Institute on Drug Abuse Humphrey Fellow. Currently, he is engaged in Ph.D. study at the Centre for Addictology of Charles University in Prague. Dr. Otiashvili currently serves as the director of the Addiction Research Center, Union Alternative Georgia in Tbilisi. He also is chair of the Board of Georgian Harm Reduction Network and a member of the Steering Committee of the Eurasian Harm Reduction Network. His main sphere of work is addiction research with the focus on HIV and injecting drug use. He serves as a Georgian principal investigator for several international collaborative studies, including those with Johns Hopkins University, Research Triangle Institute (United States), and Charles University in Prague. He is a registered lobbyist at the Georgian Parliament for reforming drug legislation.
- ❖ **Dr. George E. Woody** is a professor in the Department of Psychiatry at the University of Pennsylvania. He worked at the Drug Dependence Treatment Unit of the Philadelphia Veterans Affairs Medical Center (VAMC) and the University of Pennsylvania from 1971 until 2004 where he treated thousands of patients and was chief of the Substance Abuse Treatment Unit from 1982 until 1998. He has been principal investigator (PI) or co-PI on many research projects, beginning with a study of antidepressant pharmacotherapy for depressed methadone patients

in 1975, followed by psychotherapy studies of methadone patients, then examining risk factors associated with HIV incidence among opioid addicts. In 1999, he became the PI of the Delaware Valley Node of the National Institute on Drug Abuse Clinical Trials Network. He has authored or co-authored more than 200 publications including a recent *JAMA* publication on the results of a Suboxone study with opioid-addicted youth. He was a member of the DSM-IV Work Group on Substance Use Disorders and the Food and Drug Administration Abuse Advisory Committee, has twice been a member of the board of directors of the College on Problems of Drug Dependence, is a member of the board of directors of the Treatment Research Institute, and is a founding member of the Board of Addiction Psychiatry of the American Psychiatric Association. He has lectured nationally and internationally and was awarded a Doctor Sui Causa from Pavlov State Medical University in St. Petersburg, Russia, in September 2003.

### **Charles Parry, Ph.D., M.A., M.Sc., Medical Research Council of South Africa**

#### **Reducing Violence Against Vulnerable Women: Data From a Randomized Clinical Trial in Pretoria, South Africa**

*Presentation Summary:* A large randomized trial sponsored by the National Institute on Alcoholism and Alcohol Abuse focused on recruiting alcohol- and drug-using vulnerable women in Pretoria, South Africa, for an HIV prevention project to reduce substance use, sexual risk, and violence. This presentation will focus on 564 women who were assessed 6 months after the intervention (94% of the sample). Women reported high rates of lifetime victimization, both physically and sexually, and recent violence with their main partners at baseline. Among women who reported being sex workers (n=365), 63 percent reported ever being physically abused and 38 percent reported being sexually abused. Among women who were non-sex workers, 36 percent reported ever being physically abused and 21 percent reported ever being sexually abused. Main partners were often the perpetrators of the most recent physical and sexual abuse for both groups of women, with no significant differences between groups. These women were randomized into one of two intervention groups—revised National Institute on Drug Abuse-standard or an adapted evidence-based woman-focused intervention with violence prevention strategies. For women in the woman-focused group, there was a 66-percent reduction in the number of women who reported violence from their main partner and a 50-percent reduction in the number of women who reported abuse from their main partner after he had been using alcohol or other drugs. Dr. Parry and his colleagues concluded that these outcomes show promising results for an adapted evidence-based woman-focused intervention for vulnerable women in South Africa who use substances and are at risk for violence, HIV, and other sexually transmitted infections and face many other inequities.

- ❖ **Dr. Charles Parry** is the director of the South African Medical Research Council's Alcohol and Drug Abuse Research Unit (ADARU), which now has a staff of 25 persons based in Cape Town and Pretoria. He also has an academic appointment in the Department of Psychiatry at Stellenbosch University. He received graduate training in South Africa (M.Sc.) and in the United States (M.A., Ph.D.) in clinical and community psychology and mathematical statistics. Dr. Parry has authored more than 100 articles in peer-reviewed journals and co-authored two books: *Alcohol Policy and Public Health in South Africa* (1998) and *Alcohol and the Developing World: A Public Health Perspective* (2002). He is a member of the editorial advisory boards of *Addiction*; *Substance Abuse Treatment, Prevention, and Policy*; and the *African Journal of Drug & Alcohol Studies*. ADARU is directly involved in running more than 20 research projects funded by the South African government and the U.S. National Institutes of Health and the U.S. Centers for Disease Control and Prevention. He has worked with Dr. Wendee Wechsberg from Research Triangle Institute (RTI) over the past 7+ years and currently is working on three active projects with RTI. He served on the South African Central Drug Authority as an Executive Committee member from 2000–2005 and was actively involved in the formulation of South Africa's first National Drug Master Plan and in its revision in 2005. In 2006, he was appointed to the World Health Organization's Expert Panel on Drug Dependence and Alcohol Problems.

**Interested in  
methadone  
maintenance  
research?  
See page 35.**



### Flavio Pechansky, M.D., Ph.D., CPDD International Committee and Federal University of Rio Grande do Sul, Brazil

#### College on Problems of Drug Dependence (CPDD)

*Presentation Summary:* To avoid what has been previously reported as “Malignant Technology Transfer” (Pechansky, 2000), international fellows returning from overseas studies, as well as junior investigators who attend international meetings, must consider the adaptation of scientific materials to their own needs and culture. This can be obtained by the continuing promotion of international collaboration based on sound scientific structures, as well as a healthy network of colleagues who share commonalities among research specialties. There are currently a series of tools to allow for the maintenance of these connections, ranging from simple discussion networks to robust and sophisticated multisite collaborative projects. The National Institute on Drug Abuse and College on Problems of Drug Dependence play an important role in developing and keeping these connections open, and potential users of these materials must be identified by the scientific community, since scientific isolation may lead to “research death” in a very competitive environment such as the drug addiction field.

- ❖ **Dr. Flavio Pechansky** is associate professor and director of the Center for Drug and Alcohol Research affiliated with the Federal University of Rio Grande do Sul (UFRGS) in Brazil and the University of Delaware in the United States. Dr. Pechansky earned his specialty in psychiatry and his master’s and doctoral degrees in medicine at UFRGS, and was trained as a National Institute on Drug Abuse (NIDA)-funded Hubert H. Humphrey Fellow at the Johns Hopkins School of Public Health. He currently heads the Drug Addiction Program at Hospital de Clinicas of Porto Alegre, a teaching hospital affiliated with UFRGS. He has worked as an addiction psychiatrist for the past 25 years and has trained a number of undergraduate, specialty, and postgraduate students of medicine. Dr. Pechansky has been at UFRGS since 1995, and he holds associate research/professor positions at the University of Delaware and the University of Pennsylvania. He has an extensive career in training, consultancy, and writing in the field, with more than 100 publications including book chapters and original papers in Brazilian and international scientific journals in the areas of epidemiology and treatment of alcoholism and drug abuse, adolescent drug and alcohol experimentation, and risk behaviors for the transmission of HIV among drug users. He has served as a consultant for the Brazilian government and chair/member of scientific committees of Brazilian institutions, as well as editor and member of editorial boards of Brazilian and international scientific journals. Currently, Dr. Pechansky is assistant regional editor of the journal *Addiction* and chairs the Nucleus for Research and Study of Alcohol and Traffic, formed by a group of more than 100 professionals involved in nine studies to collect data on drugged/drunken driving and traffic behaviors in Brazil. He has been awarded prizes for papers published and presented throughout his career and received an Award of Excellence in International Leadership from NIDA. Dr. Pechansky has been elected chair of the International Committee of the College on Problems on Drug Dependence for the term 2009–2011.

### Joseph G. Perpich, M.D., J.D., JGPerpich, LLC, and Krystyna Isaacs, Ph.D., JGPerpich, LLC

#### NIDA International Virtual Collaboratory (NIVC)

*Presentation Summary:* The National Institute on Drug Abuse (NIDA) International Virtual Collaboratory (NIVC) is a suite of Internet-based software tools designed to promote interactions among NIDA International members. In the past year, we have provided support for a number of projects, including:

- NIDA International Alumni Network: The AlumniNet consists of current and alumni fellows from the NIDA Humphrey, INVEST, INVEST/CTN, and DISCA programs. The discussion forum is in active use by several subgroups.
- Inhalant Working Group (IWG): IWG members used the NIVC wiki, discussion forum, and virtual meeting room to prepare a white paper laying out a series of research issues in the field of inhalant substance abuse (*Addiction* 2009 Feb 10).
- International Women and Children’s Health and Gender Group: The 80+ members of InWomen use the discussion forum and virtual meetings to select topics and speakers for upcoming meetings and to compile critical resources.

- Volatile Solvent Abuse in Indigenous Peoples Virtual Seminar Series: A multinational research team funded by the Social Sciences and Humanities Research Council of Canada and supported by NIDA is using NIVC to record and distribute several PowerPoint presentations. Eighty-eight people registered to watch the first recording and participated in a discussion forum.

JGPerpich also is developing a Collaboration Matching Service (CMS). The purpose of the CMS is to make it easier for drug abuse researchers to identify common interests and initiate collaborations. The database will include information from NIVC, CRISP, and other relevant sources. We look forward to hearing suggestions on how to build the NIVC community in the coming years.

- ❖ **Dr. Joseph G. Perpich**, a psychiatrist and lawyer, is president of JGPerpich, LLC, an educational and professional services company that promotes collaborative research and training programs in the biomedical and behavioral sciences. Dr. Perpich was vice president for grants and special programs (1987–2000) at the Howard Hughes Medical Institute (HHMI), where he created and managed the \$100 million annual grants program for science education and international biomedical research. Prior to his appointment at HHMI, he was vice president for planning and business development at two biotechnology companies. Dr. Perpich also served as the associate director for program planning and evaluation at the National Institutes of Health (1976–1981), where he directed government-wide activities related to recombinant DNA research and regulatory policies. Dr. Perpich is a graduate of the University of Minnesota Medical School. He completed his residency in psychiatry at the Massachusetts General Hospital and the National Institute of Mental Health. At the same time, Dr. Perpich studied law at Georgetown University and received his J.D. in 1974. Among his many honors is election as a fellow of the American Psychiatric Association and the American Association for the Advancement of Science.
- ❖ **Dr. Krystyna Isaacs** is a senior program officer at JGPerpich, LLC, an educational services company. In this capacity, Dr. Isaacs is responsible for designing and evaluating the Virtual Collaboratory, a software program created to facilitate collaborations between researchers and educators. Before joining JGPerpich, she formed her own consulting company for science education program development and evaluation, and was a program official in the Howard Hughes Medical Institute's (HHMI's) International Program. While at HHMI, she was responsible for initiating the development of international science workshops and staging international meetings for HHMI grantees. Dr. Isaacs received her B.A. cum laude and with honors in biopsychology from Williams College in 1984, with election to Phi Beta Kappa. She received a Ph.D. in neuroscience in 1992 from the University of Illinois at Urbana-Champaign and was elected to Sigma Xi. She completed a 5-year postdoctoral fellowship in neurodegeneration at the National Institute of Mental Health before embarking on her science administration career.

### **Edward E. Roslof, Ph.D., Hubert H. Humphrey Fellowship Program**

- ❖ **Dr. Edward E. Roslof** has been director of the Hubert H. Humphrey Fellowship Program at the Institute of International Education (IIE) since July 2008. From 2003 to 2008, he served as director of the Fulbright Program in Russia and head of IIE's Moscow office. Prior to joining IIE, he held faculty and administrative positions at United Theological Seminary, Harvard University, and the University of North Carolina at Chapel Hill (UNC). He received his Ph.D. in Russian history from UNC. He is a Fulbright alumnus and author of several books and numerous articles on Russian religious history and culture.

### **Catherine Woodstock Strley, Ph.D., M.P.E., ACSW, Washington University School of Medicine**

#### **Ambiguity in Research Ethics With Hidden and Hiding Populations**

*Presentation Summary:* Conducting research among subpopulations with specific risk factors, such as victims of human trafficking, who are "hidden" by those who enslave them and those who engage in behavior that is against the law and are hiding from public disclosure, is difficult and problematic for researchers, Institutional Review Boards, and reviewers. Using case examples, the presentation will highlight some of the "grey" areas in this research.

- ❖ **Dr. Catherine Woodstock Striley**, an assistant research professor in the Department of Psychiatry at Washington University (WU), leads the research on a St. Louis regional effort to build the capacity of the community to identify and serve victims of human trafficking. She is the lead researcher on a national Immigrant Family Violence Institute study, a part of the Federal Domestic Violence Network funded by the Administration for Children and Families. She is the co-principal investigator with investigator and psychiatrist Dr. Kevin Black conducting a preliminary community feasibility study, which is part of a large epidemiological study of tic disorders, including Tourette's, in minority communities. Dr. Striley has been a co-investigator in a number of Dr. Cottler's studies among vulnerable out-of-treatment drug-using and criminal justice populations; she serves as the ombudsperson for a National Institute on Drug Abuse (NIDA)-funded T-32 grant and a Fogarty International training grant (Linda B. Cottler, director). Dr. Striley was the co-director and host for WU of the First Biennial Conference for Responsible Conduct of Research Education, Instruction, and Training held April 17–19, 2008, in St. Louis. She pursues a teaching and research agenda in the responsible conduct of research and serves on the WU Task Force developing material for the Responsible Conduct of Research Education, Instruction, and Training, the College on Problems of Drug Dependence (CPDD) Human Subjects Committee, the oversight committee for the WU Necessary Elements in Human Research training, and a national task force to develop Institutional Review Board training material for community-based participatory research. She was the training member of the CPDD Human Subjects Committee until this year. Dr. Striley also is a member of the WU Human Studies Committee New Protocol Committee. Her dissertation on cultural factors in care seeking among American Indian teens was funded by NIDA (R-03).

### **Wim van den Brink, M.D., Ph.D., University of Amsterdam**

#### **Similar Brain Dysfunctions in Chemical and Non-Chemical Addictions**

*Presentation Summary:* Emerging brain, behavioral, and genetic data point to substantial overlap in the vulnerabilities for compulsive pursuit of drug and nondrug (e.g., food, sex, and money) rewards. Overlapping vulnerabilities have been linked both to the mesolimbic dopamine reward system and to its failed regulation by frontal regions. This presentation will describe data from neuroimaging studies showing strong similarities in functional deficits in chemical and nonchemical addictions, especially pathological gambling.

- ❖ **Dr. Wim van den Brink** received his medical degree from the Free University in Amsterdam. From 1986 to 1987, he was a fellow at the Psychiatric Epidemiological Training program of Columbia University in New York. In 1989, he received his Ph.D. from the State University of Groningen, the Netherlands. Since 1992, he has been a professor of psychiatry and addiction at the Academic Medical Center of the University of Amsterdam. He also is the director of the Amsterdam Institute for Addiction Research. His main research interests are the etiology and treatment of addictive behaviors, including alcohol, illicit drugs, and pathological gambling. Starting with self-report assessments, his work is increasing based on neuropsychological and neuroimaging measures. He is author or coauthor of more than 250 peer-reviewed papers, and he has supervised more than 40 Ph.D. students. He is currently one of the editors of *European Addiction Research* and an assistant editor of *Drug and Alcohol Dependence*.

### **Wendee Wechsberg, Ph.D., RTI International**

- ❖ **Dr. Wendee Wechsberg** started in the field in 1977 as a clinician and treatment director. Since starting to work in HIV with injecting drug users, she has devoted her career to applied research to develop and test the efficacy of interventions among vulnerable populations of substance abusers, using both quantitative and qualitative methods to prevent HIV. The Women's CoOp is one of the Centers for Disease Control and Prevention's evidenced-based HIV prevention interventions and has been adapted in several regions of South Africa and in Russia. The underlying theoretical framework is based on empowerment theory, negotiation, and assertiveness. Currently, she is adapting HIV prevention with couples to reduce substance abuse, sexual risk, and gender-based violence and enhance communication skills and sexual monogamy in South Africa. Dr. Wechsberg collaborates with numerous faculty and researchers in institutions of higher learning in the United States and abroad and serves as a consultant to

various national and international studies. She utilizes community advisory boards for her own research projects in the United States and abroad to establish networks and linkages, in addition to obtaining feedback and keeping community stakeholders involved and informed of her community-based randomized field intervention studies. Dr. Wechsberg has published in the areas of gender and ethnicity, outreach, methadone treatment, HIV risk, and substance abuse. She is senior director of the substance abuse treatment evaluation and interventions research program at RTI International, adjunct professor at the University of North Carolina at Chapel Hill's Gillings School of Global Health, and adjunct associate professor of psychiatry at Duke University Medical School and of psychology at North Carolina State University.

Explore  
fellowship  
and funding  
opportunities.  
See page 42.

#### **Dale S. Weiss, International Program, National Institute on Drug Abuse**

❖ *Ms. Dale S. Weiss* joined the National Institute on Drug Abuse (NIDA) International Program in October 2001 as program analyst, the senior staff person who shares responsibility with the director of the NIDA International Program for planning, implementing, coordinating, and evaluating the Institute's international research, research training, and information dissemination programs. Ms. Weiss manages the fellowship and research exchange programs, numerous Small Business Innovative Research contracts to develop and implement new technology initiatives, the International Program Web page and bimonthly E-News Letter, and the Institute's international visitor program. Before joining the

NIDA International Program, Ms. Weiss served for 13 years as a contracting officer for NIDA. She also served as a contract specialist for the National Oceanic and Atmospheric Administration, the Coast Guard, and the Department of Defense. Ms. Weiss holds a bachelor's degree in management studies from the University of Maryland University College.

#### **Erin L. Winstanley, Ph.D., University of Cincinnati College of Medicine**

##### *Authorship Credits*

*Presentation Summary:* This presentation deals with the often vexing question of how to assign authorship credits in multi-authored articles. It reviews current theory and practice regarding the roles and responsibilities of authorship. It is designed to develop practical skills that will minimize unfair and unethical authorship practices. Current journal policies regarding authorship credits are discussed, as well as formal guidelines for assigning authorship credits. The presentation will then provide a model set of practical steps to assign authorship credits and discuss how to implement model procedures at the institutional level. Practical recommendations are suggested to provide collaborating authors with a process that is open, fair, and ethical.

❖ *Dr. Erin L. Winstanley* is the director of health services research and delivery at the Lindner Center of HOPE and an assistant professor in the Department of Psychiatry at the University of Cincinnati College of Medicine. Dr. Winstanley completed a postdoctoral research fellowship at the Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine and received her doctoral degree from the Johns Hopkins Bloomberg School of Public Health from the Department of Health Policy and Management in 2006. Dr. Winstanley's expertise is in behavioral health services research, and she is interested in co-occurring mental health and substance abuse disorders, health technology, access to care, and psychiatric epidemiology.


# The Methadone Research Web Guide: A great way to learn about an important treatment.



Research has demonstrated that methadone maintenance treatment is effective for heroin and prescription narcotic addiction. It has been shown to reduce illicit drug use, criminal activity, needle sharing, HIV infection rates and transmission, and more. The NIDA International Program's Methadone Research Web Guide is a convenient, comprehensive source for research findings and resources. Proponents of methadone treatment programs may find these facts useful as they prepare rationale for initiatives.

*Test your knowledge with the tutorial and get a certificate of completion.*

This flexible tutorial lets you test your knowledge in a variety of ways. Answer the questions before you review the full Methadone Research Web Guide to identify subject areas where you need more information. Answer the questions after reviewing the full guide to assess your understanding of the material. This way you can concentrate on the section of the guide that is most relevant to you. Answer all the questions correctly to obtain your personalized Certificate of Completion.



Visit [www.international.drugabuse.gov/methadone](http://www.international.drugabuse.gov/methadone)





**Saturday, June 20, 2009**

## **Joint NIDA International Forum and CPDD Satellite**

---

**8:00 p.m. – 10:00 p.m.**

**Bonanza A**

---

### **Treating Addiction During Pregnancy: Exploring Multinational Perspectives To Build a Treatment Approach Consensus**

This joint NIDA International Forum and CPDD Satellite Meeting will both initiate a global dialogue about the public health issue of drug addiction during pregnancy and determine the need and level of enthusiasm for a larger meeting to develop a consensus statement on the principles and best practices of drug addiction treatment for pregnant patients. The organizers thank Reckitt Benckiser Group Inc., which provided partial support for this meeting.

**Chair:** Hendree Jones, *Johns Hopkins University*  
**Co-Chair:** Gabriele Fischer, *Medical University of Vienna*

#### **Introduction and Goals**

- Gabriele Fischer, *Medical University of Vienna*
- Hendree Jones, *Johns Hopkins University*

#### **The Ethics of Conducting Addiction Research With Pregnant Participants**

- Marianne Springer-Kremser, *Medical University of Vienna*

#### **The Treatment of Addiction During Pregnancy: State of Data in Australia**

- Lucy Burns, *Australian National Drug and Research Centre*

#### **The Real-Life Situation for Substance-Dependent Pregnant Women in France**

- Laurent Gourarier, *Maison Blanche Hospital, Paris*

#### **Evidence-Based Research on Methadone Maintenance During Pregnancy in Israel—Outcomes and Findings Related to Nicotine Dependence**

- Einat Peles, *Tel Aviv Sourasky Medical Center*

#### **Discussion and Next Steps**

- Gabriele Fischer, *Medical University of Vienna*
- Hendree Jones, *Johns Hopkins University*



---

## Biosketches

---

### **Lucy Burns, Ph.D., M.P.H., Australian National Drug and Alcohol Research Centre**

- **Dr. Lucy Burns** is a senior lecturer at the National Drug and Alcohol Research Centre in Sydney, Australia. She holds a master's of public health, Ph.D., and a graduate certificate in health policy. Her research interests include the epidemiology of alcohol and other drug use, with a focus on particularly vulnerable populations, such as people who are homeless and pregnant women. She is currently chief investigator for the national drug monitoring systems (the Illicit Drug Reporting System and the Ecstasy and Related Drugs Reporting System) and manages a team of researchers examining the impact of flexible service provision on homeless people and the impact of alcohol and drugs on women.

### **Gabriele Fischer, Ph.D., Medical University of Vienna**

- **Dr. Gabriele Fischer** received her doctorate from the Medical University of Vienna in 1984, with a specialty in psychiatry and neurology, and did fellowship work at Washington University Medical School in St. Louis from 1986 to 1989. In 1994, she became the medical director of the Addiction Clinic at the Medical University of Vienna. Dr. Fischer has been involved in many epidemiologic and psychopharmacologic studies on substance dependence. Her pioneering work in the research of substance dependence and pregnancy resulted in several scientific publications as well as nationally and internationally funded publications (e.g., NIDA funding on the topic of a prospective multicenter trial on methadone versus buprenorphine in pregnancy). Dr. Fischer is a consultant for several international and national groups, including the United Nations Office on Drugs and Crime and the World Health Organization, and is a board member of the Quality Control Commission in Medicine in Austria. She has given more than 400 scientific presentations and has authored more than 150 scientific publications. Dr. Fischer also is involved in editorial and review work for many psychiatric journals, is a board member of several addiction societies, and is currently the chair of the College on Problems of Drug Dependence International Committee.

### **Laurent Gourarier, M.D., Maison Blanche Hospital**

- **Dr. Laurent Gourarier** is a psychiatrist and an addiction specialist. He is a lecturer on the board of GEGA (the French study group about pregnancy and addictions) at Denis Diderot University, Paris. He was involved in setting up a center for heroin injectors at the hospital school Laennec/Georges Pompidou, Paris, where he also was a clinic director for 4 years. Since 2005, he has been affiliated with La Terrasse, Hôpital Maison Blanche, in northern Paris. He co-built the French study cohort (GEGA) and still studies the long-term outcomes. Working with hepatologists in joint therapy, he focuses on hepatitis C among pregnant drug-dependent women.





### **Hendree Jones, Ph.D., Johns Hopkins University**

- **Dr. Hendree Jones** received her doctorate from Virginia Commonwealth University in 1997 and then completed a postdoctoral fellowship at the Behavioral Pharmacology Research Unit at Johns Hopkins University (JHU) School of Medicine. Dr. Jones, a licensed psychologist in the state of Maryland, is currently an associate professor in the Department of Psychiatry and Behavioral Sciences and the Department of Obstetrics and Gynecology at JHU School of Medicine. As part of her duties, Dr. Jones is the director of research for the Center for Addiction and Pregnancy, and the executive program director of Cornerstone, an aftercare program for detoxified heroin-dependent patients. Since 1994, Dr. Jones has been continuously funded by NIDA as a principal investigator designing and leading studies that focus on in utero exposure to abused substances. Among her many research interests, she is best known for her work developing both behavioral and pharmacologic treatments for drug-dependent pregnant women. She spearheads collaborative efforts with colleagues in the field and is leading the National Institute on Drug Abuse (NIDA)-funded Maternal Opioid Treatment Human Experimental Research study, a multisite randomized clinical trial comparing the maternal and neonatal safety and efficacy of methadone and buprenorphine. Dr. Jones has served on numerous review panels for NIDA, the National Institute on Alcohol Abuse and Alcoholism, Substance Abuse and Mental Health Services Administration, and Institute of Medicine. She has held multiple leadership positions within Division 28 of the American Psychological Association (APA) and is currently its president elect. She is a member of the Women's Health Research Coalition and the College on Problems of Drug Dependence, and a fellow with both the Maryland Psychological Association and the national APA. She currently serves on several editorial boards for peer-reviewed journals in the field of addiction.

### **Einat Peles, Ph.D., Tel Aviv Sourasky Medical Center**

- **Dr. Einat Peles** is a research director at the Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse Treatment and Research affiliated with the Tel Aviv Sourasky Medical Center in Israel. She is a lecturer in the Department of Psychiatry at Tel Aviv University Sackler Faculty of Medicine. She has a master's degree in biochemistry and a Ph.D. in epidemiology, both from Tel Aviv University. Her research interests include different aspects of methadone maintenance treatment patients, specifically, epidemiological studies about patient outcomes, gender differences, pregnant women, and psychiatric illnesses such as impulse control, anxiety, and depression. She also focuses on patients' sleep disorders and chronic pain.

### **Marianne Springer-Kremser, M.D., Medical University of Vienna**

- **Dr. Marianne Springer-Kremser**, a university professor, is director of the Department of Psychoanalysis and Psychotherapy at the Medical University of Vienna, Austria. She specialized in psychiatry and neurology, and is a training and supervising analyst of the Vienna Psychoanalytical Society. Her research interests cluster around psychosomatics in obstetrics and gynecology, female sexuality and medical ethics, and women's reproductive rights as human rights, for which she is an advocate. She is a member of the bioethics committee of the Austrian Chancellor. Recently, she finalized cooperation in the European Union project, "Coordination Action on Human Rights Violation," focusing on physical and mental health consequences of violence, and is currently engaged in a Daphne program "train the trainer" project evaluating multiprofessional settings, which offer counseling for victims of physical and/or sexual violence. She is member of the ethics committee of the Medical University of Vienna, which oversees the adherence of research projects to ethical standards.



# NIDA International Virtual Collaboratory (NIVC)

<http://nivc.perpich.com>

Joining geographically distant partners in collaborative research, discussion, and education.

## Collaboration + Laboratory = Collaboratory

The NIDA International Virtual Collaboratory helps members exchange information, data, online resources, and ideas to further drug abuse research and training — on a secure, password-protected site. This easy-to-use set of collaboration tools has many features.



The resource center includes user-built document libraries on a wide variety of topics. A secure wiki allows multiple researchers to create and edit documents together.



NIVC can facilitate private virtual meetings of up to 20 people. These audio or video conferences are enhanced by built-in instant messaging and the ability to share and edit documents in real time. Conferences are recordable for later playback and can be used for online trainings.



Using the new Collaboration Matching Service, NIVC members can search for colleagues based on a wide variety of demographic and research parameters, including geographic region, credentials, and research interests.



Discussion forums are linked to an e-mail listserv and can be archived for filtered searches.



This site was developed by JGPerpich with Federal funding from the SBIR Program, International Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under contract HHSN271200711284C.



NIVC is designed to work over wireless, satellite, or slow modem connections as well as over standard cable-modem or DSL lines. Training is available to help researchers implement NIVC tools in real-life situations. Registration approval is required, but usually takes 24 hours or less. To register, visit <http://nivc.perpich.com>.

# Need help negotiating the complex and sometimes bewildering challenges of scientific publication?

Visit the Web site designed specifically for addiction research!  
Authors and Expert Reviewers ...



Established by the International Society of Addiction Journal Editors (ISAJE) to train young researchers and provide continuing education for seasoned addiction scientists.

## Authors

### ■ ISAJE Author's Guide to Publishing:

- How To Choose a Journal
- Advice for Researchers From Developing or Non-English-Speaking Countries
- Publication Issues for Grad Students, Postdocs, and Other Novice Scientists
- Writing for a Peer-Reviewed Journal
- Publishing Qualitative Research
- Use and Abuse of Citations
- Authorship Issues
- Preparing Manuscripts and Responding to Referees' Reports
- Reviewing Manuscripts
- Avoiding the Seven Deadly Sins of Addiction Publishing
- Publication Ethics
- Funding and Integrity in Publishing
- Publication as a hallmark of scientific productivity

### ■ Database of 65 Peer-Reviewed Addiction Journals in 18 Languages

### ■ Tutorials on Manuscript Preparation: How To Be a Peer Reviewer and Publication Ethics

## Expert Reviewers

### ■ Tutorial on Serving as a Peer Reviewer

### ■ How to Volunteer To Be a Peer Reviewer for Papers From Low- and Middle-Income Countries

# Explore

endless possibilities that can change the world.

The NIDA International Program helps scientists like you address the global impact of drug abuse and addiction on public health by supporting international collaborative research and training programs.

## Research Support

Explore all the NIDA international funding opportunities in one place:

[http://www.international.drugabuse.gov/research/research\\_funding.html](http://www.international.drugabuse.gov/research/research_funding.html)

NIDA's scientific priority areas include linkages between HIV/AIDS and drug abuse, adolescent and prenatal tobacco exposure, methamphetamine, inhalants, and drugged driving.

## NEW! International Request for Applications

A newly issued Request for Applications (RFA-DA-10-008) seeks grant applications proposing International Research Collaborations on HIV/AIDS and Drug Use. Letters of intent are due October 18, 2009.

## International Program Announcements

Three NIDA International Program funding announcements solicit proposals for International Research Collaboration on Drug Abuse and Addiction Research in all areas of drug addiction science using three mechanisms to support awards of differing amounts:

- R01: PA-09-020
- R21: PA-09-021
- R03: PA-09-022



### For more information, contact :

National Institute on Drug Abuse  
National Institutes of Health  
U.S. Department of Health and Human Services

c/o IQ Solutions, Inc.  
11300 Rockville Pike, Suite 901  
Rockville, Maryland 20852, USA  
Telephone: +1-301-984-1471  
Fax: +1-301-984-1473  
E-mail: [ip@nida.nih.gov](mailto:ip@nida.nih.gov)  
Web site: [www.international.drugabuse.gov](http://www.international.drugabuse.gov)

NIDA also participates in several Fogarty International Center research training or grant programs:

### Fogarty Research Training Grants

- AIDS International Training and Research Program (AITRP) PAR-07-348
- International Clinical, Operational and Health Services Research Training Award for AIDS and TB (ICOHRTA—AIDS/TB) PAR-08-155

### Fogarty Research Grants

- Global Research Initiative Program (GRIP)
  - Behavioral/Social Sciences R01: PAR-07-328
  - Basic/Biomedical R01: PAR-07-329
- Brain Disorders in the Developing World (BRAIN)
  - R01: PAR-08-112
  - R21: PAR-08-113
- Fogarty International Research Collaboration Award (FIRCA)
  - Behavioral/Social Sciences R03: PAR-08-223
  - Basic/Biomedical R03: PAR-08-222
- Collaborative HIV/AIDS Studies in the Middle East and North Africa R21: PAR-08-153



### **NIDA grantees: Have you considered mentoring an international researcher through a NIDA International-funded fellowship?**

When you mentor an international researcher, your projects will benefit from the unique perspective of a highly trained foreign scientist. You will advance the field as a whole by sharing your expertise with a researcher who can take your valuable knowledge back to his or her home country.

## Fellowships

Explore all the NIDA International fellowship opportunities in one place:


<http://www.international.drugabuse.gov/research/fellowships.html>

NIDA International Program fellowships and research exchange programs provide research training and professional development opportunities for scientists at every stage of their careers:

- INVEST Research Fellowships – 12 months of post-doctoral training with a NIDA-funded scientist
- INVEST/Clinical Trials Network (CTN) Research Fellowships – 12 months of post-doctoral training with a scientist affiliated with NIDA-supported CTN Regional Research and Training Centers
- NIDA Hubert H. Humphrey Drug Abuse Research Fellowships – 10 months of guided academic study for mid-career professionals from low- and middle-income countries plus a professional drug abuse research affiliation
- NIDA Distinguished International Scientist Collaboration Awards (DISCA) and NIDA U.S. Distinguished International Scientist Collaboration Awards (USDISCA) 1- to 3-month professional visits for senior scientists and their research partners. USDISCA is for U.S. citizens and permanent residents; DISCA is for citizens of any other country.



# Congratulations 2009 Awards of Excellence. Winners!



The NIDA International Program Awards of Excellence recognize individuals for outstanding contributions to international cooperation in drug abuse research and training. The awards are presented each June at the NIDA International Forum to persons who have demonstrated outstanding and sustained support of the NIDA International Program mission in three categories: Mentoring, International Leadership, and Collaborative Research.

Additional selection criteria include:

- Innovative, creative, and pioneering achievement.
- Unique contributions by the nominee to that achievement.
- Positive change over a sustained period—not simply the potential for such change—through the nominee’s achievement.
- A qualitative and quantitative impact.
- Success in overcoming barriers, based on resources available.

## 2009 NIDA International Program Award of Excellence in Mentoring

**James (Jim) C. Anthony, Ph.D., M.Sc.**

Department of Epidemiology  
Michigan State University College of Human Medicine  
East Lansing, Michigan, United States

For 17 years, Dr. James C. Anthony has directed National Institutes of Health (NIH)-funded drug dependence epidemiology training programs for U.S. and international researchers. He has built a unique partnership with Universidad Peruana Cayetano Heredia in Lima, Peru, where he has made significant contributions to that university’s public health research training program, as well as epidemiology research throughout Latin America. In addition to his own prodigious research career—he has published more than 300 articles and books, held continuous NIH R01 award support since the 1980s, and is a K05 senior scientist—Dr. Anthony has been an extremely effective mentor: more than a dozen of his trainees have become NIH principal investigators, including one recipient of the Presidential Early Career Award and another who received a NIDA MERIT award.

## 2009 NIDA International Program Award of Excellence in Collaborative Research

### **Steffanie A. Strathdee, Ph.D.**

Department of Medicine  
University of California  
San Diego School of Medicine  
San Diego, California,  
United States

### **María Remedios Lozada Romero, M.D.**

HIV/STD Coordinator  
Baja California State  
Tijuana, Mexico

### **Carlos Magis-Rodríguez, M.D., M.P.H.**

Department of Research  
CENSIDA  
Mexico City, Mexico

Drs. Steffanie A. Strathdee, María Remedios Lozada Romero, and Carlos Magis-Rodríguez are working to understand HIV risk behaviors among drug users and sex workers on the Mexico-U.S. border, identifying key factors in the rapidly increasing risk of HIV infection in Tijuana that could lead to a resurgence throughout Mexico and Central America. An outstanding example of cross-border cooperation, the trio has worked effectively to document factors—such as injecting drug use, commercial sex work, geographic mobility, U.S. deportation patterns, history of other sexually transmitted infections, and gender—that significantly impact the evolving HIV epidemic in Tijuana. Their public health approach to shared responsibility for recognizing and treating sexually transmitted diseases between bordering countries contributes significantly to improved cross-border HIV prevention, clinical practice, and multidisciplinary global health training programs.

## 2009 NIDA International Program Award of Excellence in International Leadership

### **Ian Stolerman, Ph.D., B.Pharm.**

Section of Behavioural Pharmacology  
Institute of Psychiatry  
King's College London, United Kingdom

Applying his considerable talents as a renowned addiction researcher who helped document the addictive properties of nicotine and served as co-editor of *Drug and Alcohol Dependence* from 1992 to 2005, Dr. Ian Stolerman has contributed to international collaboration in many arenas. He was a founder and first president of the European Behavioural Pharmacology Society. His NIDA-funded Drug-Discrimination Database is a unique research tool on the neurobiological bases of addiction. From 2004 to 2006, Dr. Stolerman was president of the International Society of Addiction Journal Editors and helped to establish PARINT.org, which helps authors and peer-reviewers share research results across national and language borders, promotes international recognition of research published in non-English-language journals, and advances international communication within addiction science.

## Do you know someone worthy of an **Award of Excellence?** **2010** nominations are now open.

The NIDA International Program welcomes nominations from any individual or organization. Nominations should be accompanied by a detailed written description of the accomplishments of the nominee and an explanation of why those accomplishments merit the NIDA International Program Award of Excellence. Nominations should not exceed two pages in length. Only written material will be considered. Letters of endorsement or a curriculum vita in addition to the nomination are not necessary and will not be considered.

**NIDA**   
International Program



# THE INTERNATIONAL DRUG, ALCOHOL AND TOBACCO (IDAT) RESEARCH COMMUNITY

[www.idatresearch.com](http://www.idatresearch.com)

The IDAT Community Network site is dedicated to advancing drug, alcohol and tobacco abuse research around the world by harmonizing the work of key global research partners and institutions, effectively managing and disseminating information, and providing research capacity and technological tools to advance the exchange of ideas and generate collaborative research.


The site is a hub that collects and disseminates the latest research news from key leading organizations and researchers, provides online training, has multiple funding and resources databases, and supports networking tools to facilitate collaborative work.



IDAT Home Page

[www.idatresearch.com/Exchange](http://www.idatresearch.com/Exchange)

## THE EXCHANGE For the IDAT Research Community




Online Workgroup

For most of the site's features you do not need to sign in; however, to begin accessing the site's networking features such as looking up member profiles and setting up online workgroups you can log into the Exchange. Here, investigators can network and form workgroups. In addition an online, peer reviewed journal is now available on this site where original research can be submitted for publication.

## THE TOOLKIT For the IDAT Research Community

[www.idatresearch.com/Toolkit](http://www.idatresearch.com/Toolkit)

The site also has a toolkit that contains such things as international drug, alcohol, and tobacco abuse survey data and measures, epidemiologic information and statistics guides.



A Page From The Toolkit



This site was developed by Danya International with federal funding from the SBIR Program, International Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under contract N44DA-6-1124 and N44DA-7-1130.





# International Programme In Addiction Studies (IPAS)

## Master of Science in Addiction Studies

The International Programme in Addiction Studies (IPAS) is a unique online programme leading to a degree of Master of Science in Addiction Studies. Jointly offered by the University of Adelaide, King's College London, and Virginia Commonwealth University, the programme is available to students from all countries, although course materials are in English only. Full-time (12-month) and part-time (24-month) programme options are available. Partial scholarships are offered through the International Scholars in Addiction Studies (ISAS) program.

**IPAS aims to develop professionals from a variety of backgrounds who are fully prepared to assume leadership roles in the addictions field.** Students will study the scientific basis of addiction, public health, evidence-based interventions, research methodology, and addictions policy. Leading authorities in each of these subject areas offer lectures. Graduates are prepared to:

- Translate research on addiction into more effective treatment and prevention
- Translate research into more effective public health policies at the local, state, national, and/or international levels
- Become specialists in addiction by integrating program material into their profession

Upon completion of the degree, students receive a diploma conferred by all three universities.

### Full-time Programme Curriculum (11-week Terms)

Term One:	Introduction to Addiction Addiction Policy
Term Two:	Public Health Issues Treatment of Addiction: Pharmacotherapies
Term Three:	Treatment of Addiction: Psychosocial Research Methodology in Addictions
Term Four:	Critical Issues in Addictions Research Project in the Addictions

**2009 Application deadlines: July 15, 2009**

**Classes commence August 2009.**

For more information, see our website:  
<http://www.adelaide.edu.au/addiction>

Or contact:

Mary Loos, Ph.D. [meloos@vcu.edu](mailto:meloos@vcu.edu)  
Jason White, Ph.D. [Jason.white@adelaide.edu.au](mailto:Jason.white@adelaide.edu.au)  
Kim Wolff, Ph.D. [kim.wolff@iop.kcl.ac.uk](mailto:kim.wolff@iop.kcl.ac.uk)

### World-renowned lecturers include, among others:

T.K. Li, Director, NIAAA  
John Strang, Ian Stolerman, Michael Farrell,  
Institute of Psychiatry, Kings College  
Robert Balster, Kenneth Kendler, Charles O'Keeffe,  
VCU  
Raphael Mtechoulam, Hebrew University, Jerusalem  
Jason White, University of Adelaide  
David Nutt, Imperial College, London  
George Koob, Scripps Research Institute  
Wilson Compton and Geoffrey Laredo, NIDA  
Willem Scholten, World Health Organization  
David Courtwright, University of North Florida  
Maxine Stitzer and Hendrée Jones, Johns Hopkins  
A. Thomas McClellan, UNODC  
Martin Iguchi, UCLA, RAND Corporation  
Don Des Jarlais, Beth Israel Medical Center  
Sharon Walsh, Columbia University  
Neil Benowitz, UCSF


## Hotel Map




## Lower Level




## First Floor



**Second Floor**



**Third Floor**



**Fifth Floor**

# Program Highlights

## Friday, June 19, 2009

---

3:00 p.m. – 5:30 p.m.	International Society of Addiction Journal Editors (ISAJE) Workshops	
	❖ Practical Issues in Publishing Addiction Science	<i>Bonanza A</i>
	❖ Ethical Issues in Publishing Addiction Science	<i>Bonanza B</i>
<hr/>		
5:45 p.m. – 7:30 p.m.	NIDA International Fellowship Programs Alumni Meeting	<i>Bonanza B</i>
<hr/>		
7:30 p.m. – 8:30 p.m.	Welcome and Networking Session	<i>Southern Pacific BCDE</i>

## Saturday, June 20, 2009

---

8:30 a.m. – 11:45 a.m.	Plenary Session	<i>Rose B Ballroom</i>
	❖ Welcome Remarks and Introduction	
	❖ Disorders of Desire: Shared Brain Vulnerabilities to Drug and Non-Drug Rewards	
	❖ National Institute on Drug Abuse Progress, Priorities, and Plans for the Future	
	❖ 2009 NIDA International Program Awards of Excellence	
<hr/>		
11:45 a.m. – 1:00 p.m.	Optional Networking Lunch (Fee required)	<i>Pavilion E</i>
<hr/>		
12:30 p.m. – 4:15 p.m.	Exhibits and Demonstrations of Collaboration, Training, and Research Tools and Opportunities	<i>Rose B Ballroom</i>
<hr/>		
1:00 p.m. – 2:30 p.m.	Concurrent Breakout Sessions	
	❖ Ethical Issues in the Conduct of Research	<i>Bonanza A</i>
	❖ Multinational Assessment and Prevention of Inhalant Abuse	<i>Bonanza B</i>
<hr/>		
2:45 p.m. – 4:15 p.m.	Concurrent Breakout Sessions	
	❖ The New World of Naltrexone: New Formulations, New Indications	<i>Bonanza B</i>
	❖ The Interaction of Violence and Substance Use Affecting Women's Treatment and Interventions in the Global Arena: What Is Known and What Is Needed Next	<i>Bonanza A</i>
<hr/>		
8:00 p.m. – 10:00 p.m.	Joint NIDA International Forum and CPDD Satellite—Treating Addiction During Pregnancy: Exploring Multinational Perspectives To Build a Treatment Approach Consensus	<i>Bonanza A</i>

## Monday, June 22, 2009

---

8:00 p.m. – 10:00 p.m.	Joint NIDA International Forum and CPDD Workshop—International Research Posters	<i>Rose Ballroom Foyer</i>
------------------------	---	----------------------------

## Tuesday, June 23, 2009

---

7:00 a.m. – 8:00 a.m.	Forum Review and Future Planning	<i>Southern Pacific EF</i>
-----------------------	----------------------------------	----------------------------